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ABSTRACT 
 Patients with atrial fibrillation (AF) are at increased risk of stroke. Warfarin 
anticoagulation therapy reduces the incidence of stroke and increases the 
incidence of hemorrhagic events. This dissertation further informs the decision to 
use anticoagulation therapy in AF patients by examining outcomes in patients 
with major hemorrhages, further examination of stroke risk in diabetic patients 
with AF, and by evaluating the association between warfarin and stroke while 
accounting for competing risk events.  
 These studies utilized data from the AnTicoagulation and Risk Factors In 
Atrial Fibrillation (ATRIA) and ATRIA-CVRN (Cardiovascular Research Network) 
(Study 1 only) studies which consist of patients from Kaiser Permanente 
Northern and Southern California. Study 1 examined short and long-term 
mortality in patients who experienced major gastrointestinal (GI) hemorrhages. In 
the ATRIA cohort, patients using and not using warfarin at the time of GI 
hemorrhage were equally likely to die within 30-days, while in ATRIA-CVRN, 
patients using warfarin were much less likely to die within 30-days (adjusted 
  vii
mortality rate ratio (aMRR): 0.33, 95% CI: 0.16–0.70). For longer-term mortality, 
both cohorts were consistent with a reduced mortality rate among patients whose 
GI hemorrhage occurred while using warfarin. Study 2 assessed the association 
between diabetes characteristics (duration of diabetes and glycemic control) and 
incidence of ischemic stroke among patients with AF and diabetes. Duration ≥ 3 
years was associated with a large increase in rate of stroke (adjusted hazard 
ratio (aHR): 2.04, 95% CI: 1.27–3.26) compared to patients with duration < 3 
years. Patients with the poorest glycemic control (hemoglobin A1c (HbA1c) 
values ≥ 9.0%) did not have an increased rate of ischemic stroke compared to 
patients with HbA1c < 7.0%. Study 3 evaluated the association between warfarin 
and thromboembolism in analyses that did and did not account for competing 
death events. In analyses not accounting for competing events, the adjusted HR 
was 0.61 (95% CI: 0.54–0.69), and after accounting for competing death events 
this association was attenuated (aHR: 0.87, 95% CI: 0.77–0.99).  
 In summary, these studies add to the literature about the benefits of 
warfarin therapy and risk of stroke in patients with AF, findings that can improve 
decisions about use of anticoagulants in patients with AF.   
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INTRODUCTION 
Atrial fibrillation (AF) is the most common significant cardiac arrhythmia, 
with an estimated 3 million adults affected in 2005 and projections ranging from 
5.6–15 million adults with AF in the United States by the year 2050.1–4 Its 
prevalence is strongly associated with increasing age, with a prevalence of 
nearly 10% among those 80 years of age or older and a median age of 75 
years.1, 4 The expected increase in prevalence by the year 2050 is largely due to 
the shifting of the age distribution towards older ages, with expectations of more 
than 50% of affected individuals aged 80 years or older.2, 4 AF is characterized by 
uncoordinated atrial electrical activation with rapid and irregular atria contraction. 
The abnormal atrial contraction is associated with an abnormal and frequently 
rapid ventricular response. Failure of the atria to contract normally may result in 
blood pooling in the atria, in particular the left atrial appendage, and forming 
clots. These clots can then move into the cerebral circulation resulting in 
thromboembolic (ischemic) strokes. Additionally, the rapid ventricular response 
may result in the ventricles pumping blood less efficiently.1  
AF is associated with a 5-fold increase in the risk of ischemic stroke, and 
accounts for 15% of all strokes nationally, including more than 36% of strokes in 
those 80 years of age or older.5, 6  Warfarin anticoagulation therapy, the current 
standard of care, is associated with reduced risk of ischemic stroke in patients 
with AF, but also an increased risk of major hemorrhagic events.7–15  In a cohort 
study conducted within clinical practice, warfarin therapy was associated with 
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reduced risk (Hazard Ratio (HR):0.49, 95% CI: 39%–60%) of ischemic stroke 
and a 97% increase in risk (95% CI: 24%–213%) of intracranial hemorrhage 
(ICH) compared with no warfarin therapy.9  Increases in risk of extracranial 
hemorrhage have been observed in randomized trials.9–11 
Despite the benefits of warfarin therapy, many patients with AF are not 
prescribed warfarin.16–20 In surveys of physicians, a major factor for the 
underutilization of warfarin is the fear of causing major hemorrhage in patients, 
especially among older adults.21–23 The avoidance of anticoagulation in older 
adults occurs despite evidence that the net clinical benefit, which balances the 
reduction in stroke incidence with the increase in major hemorrhage attributable 
to warfarin, is greatest in the oldest patients.24 Decision aids to predict the risk of 
stroke and warfarin-associated hemorrhage are available to help aid physicians 
in prescribing or continuing therapy.25–27  With approval of novel anticoagulant 
alternatives to warfarin, and their likely increased role in managing stroke 
prevention, better understanding of the risk of stroke among AF patients and the 
risks of major bleeding complications from warfarin in current use are needed.  
This dissertation examines the risk and impact of major adverse events 
occurring in patients with AF and adds new information to aid the decision of 
whether to use anticoagulation therapy in these patients. In study 1, we examine 
the association between warfarin therapy and risk of death among patients who 
have experienced a major gastrointestinal hemorrhagic event. In study 2, we 
evaluate which characteristics of diabetes (including duration of diabetes and 
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glycemic control), an established risk factor for stroke in AF patients, are most 
important in predicting incident ischemic stroke among diabetic AF patients. In 
study 3, we assess the association between warfarin therapy and stroke while 
accounting for death events as a competing risk.   
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WARFARIN ANTICOAGULATION THERAPY AND MORTALITY FOLLOWING 
MAJOR GASTROINTESTINAL HEMORRHAGES 
- This study was published previously as “Ashburner, et al. Comparison of 
frequency and outcome of major gastrointestinal hemorrhage in patients with 
atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and 
ATRIA-CVRN cohorts. Am J Cardiol. 2015 Jan 1;115(1):40–6. 
 
BACKGROUND 
There are only limited data about short- and long-term health sequelae of 
AF patients following hemorrhagic events on and off warfarin therapy. Prior work 
has shown that compared with patients not taking anticoagulant therapy, patients 
on warfarin therapy at the time of intracranial hemorrhage have a markedly 
increased risk of 30-day mortality.28 The reduction in mortality from ischemic 
stroke and increase in mortality from intracranial hemorrhage are important 
factors in weighing the net clinical benefit of anticoagulant therapy.24 
To date, there have been few studies evaluating outcomes of AF patients 
who have experienced gastrointestinal hemorrhages (GI), the most common 
extracranial hemorrhage site and most common site of important warfarin-related 
bleeding. While intracranial hemorrhages are more severe, extracranial 
hemorrhages are more common (approximately 60% of major hemorrhagic 
events among AF patients in ATRIA and up to 90% in pooled analyses of 
randomized trials) and can be fatal.7, 29, 30 Among warfarin users, intracranial 
hemorrhages are much more likely to result in death than GI hemorrhages.29 
Although warfarin exposure significantly worsens outcomes from intracranial 
hemorrhage, it is not known whether anticoagulation similarly affects mortality 
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from GI hemorrhage. This is a particularly relevant question for AF patients as it 
may further inform the decision to use warfarin therapy. These considerations 
apply as well to the novel anticoagulants for which GI hemorrhage remains an 
important concern.31 
The current study aimed to assess the association between warfarin use 
at the time of GI hemorrhage and the rate of short-term (30-days) and longer-
term (1-year) mortality in AF patients in clinical care. We based the study in two 
large, community-based cohorts with comprehensive follow-up and clinical 
adjudication of hemorrhages. 
 
METHODS 
Source Population 
Patients included in these analyses were members of two cohort studies 
of patients with AF from Kaiser Permanente (KP) Northern and Southern 
California, two large integrated health care delivery systems. The Anticoagulation 
and Risk Factors in Atrial fibrillation (ATRIA) cohort includes 13,559 adults aged 
18 and older with diagnosed non-valvular AF who received care with KP 
Northern California.9 The ATRIA-CVRN (Cardiovascular Research Network) 
cohort includes 33,247 adults aged 18 and older with incident non-valvular AF 
who were enrolled in either KP Northern or KP Southern California.32 In each 
sample, cohort members were identified by searching electronic inpatient, 
outpatient, and electrocardiographic databases for physician-assigned 
  
6
International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9) diagnostic codes of AF (427.31, 427.32). ATRIA patients were identified 
between July 1996 and December 1997 and followed through September 2003. 
ATRIA-CVRN patients were identified between January 2006 and June 2009, 
with follow-up through June 2009. Since we were interested in non-transient, 
nonvalvular AF, we excluded AF patients with diagnosed mitral stenosis (ATRIA 
only), valvular repair or replacement (ATRIA only), transient postoperative AF, or 
concurrent hyperthyroidism. Unlike the ATRIA cohort, the ATRIA-CVRN cohort 
did not exclude patients with mitral stenosis or a history of a valve replacement; 
such patients accounted for only 1.5% of the ATRIA-CVRN cohort. 
Gastrointestinal Hemorrhagic Events 
We focused on patients who were hospitalized for major GI hemorrhage 
during the observation period of the full ATRIA and ATRIA-CVRN studies. GI 
hemorrhages were identified by searching comprehensive hospitalization and 
billing databases for primary discharge diagnoses (Appendix 1). Major GI 
hemorrhages were defined as fatal (death during hospitalization) or requiring 
transfusion of 2 or more units of packed red blood cells. GI hemorrhages not 
leading to hospitalization were excluded. Since KP is an insurer as well as a 
health care provider, cohort members admitted to facilities outside of the network 
were still identified by our search strategy. Each potential GI hemorrhagic event 
was reviewed by a physician or nurse who was trained in medical record reviews 
using a formal study protocol and who was unaware of the study hypotheses. 
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This resulted in identification of 712 patients in the ATRIA cohort who 
experienced a hospitalization for a validated GI hemorrhage, with 414 (58%) 
classified as major hemorrhages. Six hundred one (601) patients in the ATRIA-
CVRN cohort experienced a validated GI hemorrhage, with 361 (60%) classified 
as major hemorrhages.  
Definitions of variables 
Warfarin use at the time of the GI hemorrhagic event was assessed 
through manual review of the admission medical record. Patients were 
considered exposed and using warfarin if the admission medical record indicated 
that they were taking warfarin within 5 days before admission for GI hemorrhage. 
Warfarin use was not updated to reflect use after the GI hemorrhage. We 
recorded the admission international normalized ratio (INR) value for each 
patient prior to reversal of warfarin effect. For the ATRIA cohort, we recorded the 
number of units of blood that were transfused and whether fresh frozen plasma 
(FFP) was used.  For the ATRIA-CVRN cohort we recorded whether the number 
of transfused units of blood was ≥ 2 and did not record use of FFP. 
The outcomes of interest included deaths within 30-days or within 1-year 
following the GI hemorrhagic event. Deaths were determined through reviewing 
medical charts, health plan databases, Social Security Administration vital status 
file, and the comprehensive California State death certificate registry. 
Patient characteristics were obtained from administrative databases. Low 
educational attainment status (< high school graduation) and low income status 
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(annual household income < $35,000) were assigned from geocoding based on 
U.S. Census block group data. Current smoking status was based on patient 
self-report. Prior GI hemorrhage, prior fall, and history of comorbid conditions, 
including ischemic stroke, intracranial hemorrhage, diabetes mellitus, coronary 
disease, hypertension, chronic heart failure, chronic liver disease, cancer 
(excluding non-melanomatous skin cancer), dementia, lung disease (ATRIA-
CVRN only), and transient ischemic attack (ATRIA-CVRN only) were collected 
from clinical inpatient and ambulatory databases using validated algorithms and 
were assessed using data during the five years prior to the date of hospitalization 
of GI hemorrhage. Kidney dysfunction (defined as estimated glomerular filtration 
rate [eGFR] < 30 ml/min/1.73 m2) was calculated from the most recent laboratory 
values prior to the GI hemorrhage using the Chronic Kidney Disease 
Epidemiology (CKD-EPI) Collaboration formula.33 Patients without an eGFR 
value within the six months prior to the GI hemorrhage were considered to have 
normal renal function. The most recent outpatient hemoglobin (Hgb) value from 
30 days prior to 1-year prior to the GI hemorrhage was used to identify patients 
with anemia (female: hemoglobin [Hgb]) <13.5 g/L, male: Hgb<12.0 g/L). Patients 
without a hemoglobin value during this time period were considered not to have 
anemia. Use of aspirin at the time of GI hemorrhage was determined from 
manual review of the admission medical record. Use of other antiplatelet agents, 
statins or other lipid lowering agents, angiotensin converting enzyme (ACE) 
inhibitors, and angiotensin II receptor antagonists (ARBs) at the time of GI 
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hemorrhage were determined from information based on dispensings from health 
plan ambulatory pharmacy databases. For all patients, the CHADS2,26 CHA2DS2-
VASc,34 ATRIA stroke,35 HAS-BLED,36 and ATRIA hemorrhage risk scores were 
calculated.25 
Statistical analysis 
For the analysis of warfarin use at the time of GI hemorrhage and 30-day 
mortality, the index date was the date of admission to the hospital for GI 
hemorrhage. Follow-up began the day after admission and ended at the first 
occurrence of any of the following: death, censoring due to withdrawal from the 
KP network, or after 30-days. For the longer-term mortality analysis, the index 
date was also the day after admission for the GI hemorrhage and ended at the 
first occurrence of any of the following: death, censoring due to withdrawal from 
the KP network, or one year after baseline. 
We found heterogeneity in the crude association of warfarin use at the 
time of GI hemorrhage and mortality between the two cohorts (ATRIA and 
ATRIA-CVRN), and therefore decided to examine the cohorts separately rather 
than as a combined dataset (Appendix 2). We conducted descriptive and 
stratified analyses to examine the distribution of potential confounders among 
those using and not using warfarin in each cohort. Cox proportional hazards 
regression was used to estimate the crude and adjusted mortality rate ratio 
(mRR) for the association between warfarin use at the time of GI hemorrhage 
and 30-day mortality as well as with mortality over 1-year of follow-up (SAS, 
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version 9.4 [SAS Institute, Cary, North Carolina]). Additionally, we examined 
models stratified by age group (<85, ≥ 85 years), and where we divided the 
exposed group (those using warfarin at the time of GI hemorrhage) by INR at the 
time of hemorrhage (INR ≥ 3 and INR < 3) and compared both INR categories to 
those not using warfarin at the time of hemorrhage. 
To assess and control for confounding, we utilized propensity score 
adjustment to balance measured risk factors for death between those using and 
not using warfarin at the time of GI hemorrhage. Propensity scores were 
generated from logistic regression models to estimate the predicted probability of 
using warfarin at the time of GI hemorrhage versus not using warfarin.37 
Propensity scores were generated for 4 separate analyses: 1) ATRIA sample: 
30-day mortality, 2) ATRIA-CVRN sample: 30-day mortality, 3) ATRIA sample: 
long-term mortality, 4) ATRIA-CVRN sample: long-term mortality. All covariables 
defined above, were assessed for potential inclusion in propensity score models. 
For each of these 4 analyses, we fit a preliminary proportional hazards 
model predicting death that included all these covariates to determine the 
strength of the association of each covariable with either short or longer-term 
mortality. To avoid including non-confounding predictors of warfarin use in the 
propensity score model, only those variables with a hazard ratio (or 1/hazard 
ratio) of at least 1.2 from the preliminary outcome model were used to create the 
propensity scores. After generating the propensity scores, we trimmed 2.5% of 
patients on both extremes of the propensity score distribution to improve 
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comparability of the warfarin and non-warfarin use groups. Further trimming was 
performed if necessary to limit the analysis to patients within a propensity score 
range that was common to both patients using and not using warfarin at the time 
of GI hemorrhage (total trimming range: 29–46 observations). These 
observations were outside the primary area of overlap of the propensity scores 
and increase residual confounding.38 The Cox proportional hazards models were 
adjusted for propensity score quintile (Appendix 3). We also performed additional 
analyses where the propensity score stratification was more finely divided (8 and 
10 strata, respectively). Comparison of the characteristics of warfarin users and 
non-users in each of the five propensity score quintiles showed similar 
distributions for covariates included in the propensity score model for both ATRIA 
and ATRIA-CVRN (Appendix 3a–3d). 
A sensitivity analysis to determine the minimum amount of bias that would 
convert our observed association in ATRIA-CVRN for 30-day mortality to a null 
finding was performed by simulating an unknown confounder and varying the 
prevalence of the confounder among those using warfarin, the prevalence of the 
confounder among those not using warfarin, and the strength of the association 
between the confounder and 30-day mortality. 
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RESULTS 
Characteristics of the study population 
 Among the 414 ATRIA patients with major GI hemorrhages, 54% were 
taking warfarin. Major GI hemorrhages included 205 (49%) upper GI bleeds, 94 
(23%) lower GI bleeds, and 115 (28%) where the location was undetermined by 
the time of hospital discharge. At the time of GI hemorrhage, patients using 
warfarin were younger, much less likely to be using aspirin, less likely to have 
diagnosed dementia or a prior history of GI hemorrhage and were more likely to 
have a prior history of ischemic stroke and to be using lipid-lowering agents and 
ACE inhibitors, compared with patients not using warfarin. There was no 
statistically significant difference in CHADS2, CHA2DS2-VASc, or ATRIA stroke 
risk scores between patients using or not using warfarin at the time of their 
bleeding event, while warfarin users had clearly lower HAS-BLED and ATRIA 
hemorrhage risk scores (Table 1.1). Characteristics of warfarin users and non-
users within propensity score quintiles were quite similar (Appendix 3a–3d). 
Overall, 398 (96%) patients were transfused with a median number of 3.0 (IQR) 
units of blood.  Among warfarin users, the median INR at presentation was 3.0 
(IQR).  FFP was used in 56% of warfarin users. 
 Among the 361 ATRIA-CVRN patients with major GI hemorrhages, 58% 
were taking warfarin. The distribution of anatomical sites was very similar to that 
of the ATRIA cohort with 176 (49%) upper GI bleeds, 99 (27%) lower GI bleeds, 
and 86 (24%) undetermined. Similar to those in the ATRIA cohort, GI 
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hemorrhage patients in ATRIA-CVRN using warfarin were younger, less likely to 
be women, less likely to have a history of falls, prior GI hemorrhage, or dementia 
and much less likely to be using aspirin. In the more recent ATRIA-CVRN cohort 
the use of lipid-lowering agents was far more common and GI bleed patients on 
warfarin were prescribed such agents more frequently than those not taking 
warfarin. GI bleed patients on warfarin were less likely to have pre-existing 
anemia. As with the ATRIA experience, there was no statistically significant 
difference in CHADS2, CHA2DS2-VASc, or ATRIA stroke scores between patients 
using or not using warfarin at the time of their bleeding event, while warfarin 
users had lower HAS-BLED and ATRIA hemorrhage risk scores (Table 1.1). 
Comparison of the characteristics of warfarin users and non-users in each of the 
five propensity score quintiles showed similar distributions for covariates included 
in the propensity score model (Appendix 3a–3d). Overall, 357 (99%) of patients 
were transfused with ≥ 2.0 (IQR) units of blood. Among warfarin users, the 
median INR at presentation was 3.2 (IQR). 
Warfarin usage and 30-day mortality 
In the ATRIA cohort, 11.2% (n=25) of major GI hemorrhage patients taking 
warfarin died within 30-days (76% died in hospital), compared with 13.1% (n=25) 
of patients not taking warfarin (76% in hospital) (unadjusted RR=0.84, 95% CI: 
0.48–1.46) (Table 1.2). In multivariable models that adjusted for propensity score 
quintile, warfarin use at the time of GI admission was not associated with short-
term mortality following GI hemorrhage (adjusted mRR=0.97, 95% CI: 0.54–1.74) 
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(Figure 1.1a). 
In contrast, in ATRIA-CVRN, only 4.8% (n=10) of major GI hemorrhage 
patients taking warfarin died within 30-days (40% in hospital), compared to 
13.9% (n=21) of such patients not taking warfarin (43% in hospital) (unadjusted 
mRR=0.33, 95% CI: 0.16–0.70) (Table 1.2).   In multivariable models that 
adjusted for propensity score quintile, warfarin use at the time of GI admission 
was associated with a much lower short-term mortality rate in ATRIA-CVRN 
although the confidence interval around the point estimate was wide (adjusted 
mRR=0.38, 95% CI: 0.17–0.83) (Figure 1.1b).  
Warfarin use appeared to be more strongly associated with lower 30-day 
mortality among the oldest group of patients, i.e., aged 85 years and older.  In 
the ATRIA cohort the adjusted mRR (95% CI) was 0.75 (0.28–2.03) for patients ≥ 
85 years (n=94) versus 1.16 (0.56–2.41) for those <85 years (n=320). In ATRIA-
CVRN, warfarin appeared to be associated with reduced mortality among all 
ages but, as in ATRIA, the largest observed association again was seen among 
older individuals (adjusted mRR [95% CI]:  ≥ 85 years (n=62): 0.15 [0.02–1.27]), 
< 85 years (n=299): 0.50 (0.20–1.23). 
Warfarin usage and long-term mortality 
The unadjusted mortality rate ratio for 1-year of follow-up comparing 
patients using warfarin to those not using warfarin in ATRIA was 0.66 (95% CI: 
0.48–0.92) (Table 1.3). The point estimate reduction in mortality rate associated 
with warfarin use persisted after adjustment for propensity score quintile 
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(adjusted mRR [95% CI]: 0.76 [0.54–1.07]) (Figure 1.2a). In ATRIA-CVRN, the 
unadjusted mortality rate ratio was 0.61 (95% CI: 0.38–0.97) (Table 1.3). After 
adjusting for propensity score quintile, the point estimate suggested a reduction 
in mortality among those using warfarin (adjusted mRR [95% CI]: 0.69 [0.42–
1.13]). Most of the reduced risk in the warfarin group appears early during the 
follow-up period (Figure 1.2b). 
Anticoagulation intensity 
After dividing the exposed group into two INR categories (INR ≥ 3 and INR 
< 3), sample sizes are smaller and confidence intervals are wide. However, 
results are similar to our overall analysis. In the short-term analysis, we still 
observe a null result in the ATRIA cohort and a large association in the ATRIA-
CVRN cohort (Appendix 4). 
Sensitivity analyses 
The adjusted mortality rate ratios for 30-day and long-term mortality with 
adjustment by propensity score strata that are more finely divided (8 and 10 
strata) were similar to the main analyses where propensity scores were divided 
into 5 strata (Table 1.4). 
In Table 1.5, we demonstrate that an unmeasured confounder would need 
to have an extreme difference in prevalence between warfarin users and non-
users, and would need to have a very large association with mortality in order to 
wholly explain our observed association. Additionally, such a confounder would 
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also need to be completely uncorrelated with other variables we are already 
controlling for, since if there is any correlation with other controlled variables then 
we are already partially controlling for this unmeasured confounder. 
 
DISCUSSION 
We compared the mortality rates of patients sustaining a major GI 
hemorrhage on- versus off-warfarin therapy in 2 very large, community-based 
cohorts of patients with AF. Patients using warfarin at the time of the GI 
hemorrhage had a reduced 30-day mortality rate in the more contemporary 
ATRIA-CVRN cohort. In the older ATRIA cohort, the 30-day mortality rate was 
essentially the same regardless of whether the patient had been using warfarin 
or not. When stratified by age, warfarin use was associated with a better 
outcome among the oldest individuals (≥ 85 years) in both cohorts, although the 
age-stratified results were conducted among small groups and were not 
statistically significant. For longer-term mortality, the data from both cohorts were 
consistent with a reduced mortality rate among patients whose GI hemorrhage 
occurred while using warfarin, although the confidence intervals for the adjusted 
mortality rate ratios included the null value of 1.0 and most of the reduction in 
rate in the warfarin group for the ATRIA-CVRN cohort occurred early during 
follow-up.  
Our finding that warfarin users had the same or lower 30-day mortality risk 
following major GI hemorrhage clearly contrasts with warfarin’s effect on 
intracranial hemorrhage where anticoagulation markedly worsens outcome.28, 39 
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In prior ATRIA analyses, warfarin use at the time of intracranial hemorrhage was 
independently associated with a 62% increased odds of 30-day mortality. The 
lessened mortality risk with GI hemorrhage may be the result of less severe 
lesions bleeding on warfarin and/or reversibility of warfarin’s hemorrhagic 
effect.40 In contrast, patients who experience intracranial hemorrhages while on 
warfarin often face grim outcomes before the effect of warfarin can be reversed.41 
Part of the observed mortality effect in GI hemorrhage may be related to residual 
confounding by underlying comorbidity despite our propensity score analysis. 
Indeed, the lower long-term mortality we observed in patients taking warfarin at 
the time of GI bleed is consistent with preferential use of warfarin in healthier 
patients, since the impact of a resolved GI hemorrhage must be small by ≥ 30 
days.   
More generally, the anticoagulation decision for patients with AF depends 
on the expected net clinical benefit of warfarin, which summarizes the difference 
in thromboembolic events (primarily ischemic stroke) prevented and hemorrhagic 
events induced.25–27, 34–36 Net clinical benefit depends on both the rates of events 
on and off warfarin and the severity of the different types of events. Extracranial 
hemorrhages are included in some,42, 43 but not all,24 proposed calculations of net 
clinical benefit. The current analyses, as well as our prior work on intracranial 
hemorrhages28 make clear that there is a different distribution of severity for both 
thromboembolic and hemorrhagic events depending on whether the patient was 
taking warfarin at the time of the event. Our current work demonstrates that GI 
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hemorrhages on warfarin are certainly no worse and may be less life-threatening 
than those occurring off warfarin. Although confidence intervals were wide, 
reduced GI hemorrhage mortality appeared greatest for the oldest patients, a 
group at the highest risk of hemorrhage and least likely to be prescribed 
warfarin.17, 24, 44–46  In all, our results add to the expected net clinical benefit of 
warfarin, particularly among older patients with AF.    
This study was strengthened by including a large number of validated 
major GI hemorrhages, from 2 separate large cohorts from KP Northern and 
Southern California. These cohorts were community-based with comprehensive 
follow-up, with the result that the findings are likely to be broadly generalizable. 
All events were adjudicated by physicians or nurses using a standardized 
medical record review protocol. Such an approach minimizes error in case 
ascertainment and determination of warfarin exposure, a problem faced by 
studies using only administrative data. Additionally, we utilized propensity score 
modeling tailored to each analysis to control for confounding. This approach 
ensured that comparisons were made between patients who had similar 
distributions of measured confounders, thereby reducing confounding.38 We 
observed a much larger association between warfarin and reduced short-term 
mortality in the more contemporary ATRIA-CVRN cohort. This difference was 
mainly due to a lower mortality rate in warfarin users in this cohort, while mortality 
rates were similar among non-warfarin users in the 2 cohorts. It is not clear why 
the GI hemorrhage mortality rate was lower among warfarin users in the ATRIA-
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CVRN cohort, although part of the difference may be explained by the role of 
chance. Even with these differences across cohorts, our results make clear, at 
the least, that GI hemorrhages occurring in patients taking warfarin pose no 
increase in mortality risk compared to GI hemorrhages occurring in patients not 
taking warfarin. Our results are indirectly applicable to the use of novel 
anticoagulants for AF since GI hemorrhages remain a major concern with these 
agents.31 There are very limited data on outcomes of GI hemorrhages comparing 
patients on novel anticoagulants versus patients not taking anticoagulants. It 
does appear that the case fatality rate for extracranial hemorrhages on novel 
agents is the same or lower than for extracranial hemorrhages on warfarin.47 As 
such, the reassuring results of our analysis should apply to GI hemorrhages on 
novel agents. 
This study also has several potential limitations. It is possible that there is 
residual confounding by indication due to underlying comorbidity, i.e. patients not 
receiving warfarin may have been “sicker”. These patients may be at particularly 
high mortality risk and may not be anticoagulated for this reason. We 
aggressively addressed confounding by propensity score approaches. Further, 
we also included terms in our regression models for variables that were not 
balanced (P<0.20) in at least 4 quintiles of the propensity score and the mortality 
rate ratios were similar to models only adjusted for propensity score quintile. We 
also performed additional analyses where the propensity score stratification was 
more finely divided (8 and 10 strata), and the results were similar (data not 
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shown). Despite the advantages of propensity score methods, they do not 
account for unmeasured confounders.  It is likely that residual confounding 
persists in our comparison of warfarin users versus non-users.  However, it is 
unlikely that any residual confounding is large enough to reverse the association 
observed for short-term mortality in the ATRIA-CVRN cohort.  
In conclusion, this study demonstrates that gastrointestinal hemorrhages 
on warfarin are certainly no worse and may be less life-threatening than those 
occurring off warfarin.  This finding is markedly different from intracranial 
hemorrhage where warfarin substantially increases mortality. Our results should 
provide reassurance to physicians and patients concerned about anticoagulant-
related GI hemorrhage and add another factor favoring anticoagulation in clinical 
decision-making for patients with AF.   
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Table 1.1: Baseline Patient Characteristics by Use of Warfarin at the Time of Gastrointestinal Hemorrhage: Among 
414 Patients from the ATRIA Study and 361 Patients from the ATRIA-CVRN Study 
 
 ATRIA ATRIA-CVRN 
 Warfarin use at 
GI hemorrhage 
(n = 223) 
No Warfarin at 
GI hemorrhage 
(n = 191) 
P-Value Warfarin use at 
GI hemorrhage  
(n = 210) 
No Warfarin at 
GI hemorrhage 
(n = 151) 
P-Value 
Patient Characteristics       
Age, mean (SD) 77.4 (7.1) 79.9 (9.3) 0.002 76.0 (8.0) 77.9 (9.1) 0.03 
Race/ethnicity   0.78   0.33 
     Asian/Pacific Islander 5.8% 6.3%  9.5% 9.3%  
     Black 5.4% 7.9%  8.1% 13.3%  
     Hispanic ethnicity 7.2% 6.8%  15.7% 9.9%  
     Other/Unknown 1.4% 0.5%  1.0% 0.7%  
     White 80.3% 78.5%  65.7% 66.9%  
Gender, women 43.5% 45.0% 0.75 40.5% 48.3% 0.14 
Low educational attainment 5.8% 3.7% 0.31 27.1% 29.1% 0.68 
Low annual household income 9.9% 7.9% 0.47 15.7% 13.9% 0.63 
Current Smoker, Yes   0.63   0.57 
     Yes 4.9% 3.1%  4.8% 7.3%  
     No 80.3% 82.7%  89.1% 87.4%  
     Unknown 14.8% 14.1%  6.2% 5.3%  
Comorbidities and 
Contraindications 
      
History of mechanical falls 10.8% 11.5% 0.81 12.4% 21.2% 0.02 
Prior GI hemorrhage 13.9% 20.9% 0.06 14.8% 20.5% 0.15 
Prior ischemic stroke 15.7% 12.0% 0.30 9.5% 8.0% 0.60 
Diabetes mellitus 30.5% 31.4% 0.84 41.4% 45.0% 0.49 
Coronary disease 45.3% 43.5% 0.71 42.4% 39.1% 0.52 
Hypertension 66.8% 70.7% 0.40 91.4% 94.7% 0.24 
Chronic heart failure 57.4% 53.9% 0.48 48.6% 49.7% 0.84 
Dementia 7.6% 13.1% 0.07 3.3% 7.3% 0.09 
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Chronic liver disease 4.0% 4.2% 0.94 3.3% 5.3% 0.36 
Significant kidney dysfunction 21.1% 21.5% 0.92 12.4% 13.9% 0.67 
Cancer
†
 22.0% 22.5% 0.90 22.9% 23.2% 0.94 
Anemia‡ 47.1% 49.2% 0.67 55.2% 65.6% 0.05 
Lung disease n/a n/a  47.6% 44.4% 0.54 
Transient ischemic attack n/a n/a  7.1% 6.0% 0.66 
Medications at Admission       
Aspirin 13.9% 56.5% <0.001 38.6% 63.6% <0.001 
Other antiplatelet therapies 0.0% 1.6% 0.10 10.5% 12.6% 0.53 
Lipid-lowering agents 12.1% 6.3% 0.04 63.3% 51.0% 0.02 
ACE inhibitors 44.4% 35.1% 0.05 38.6% 40.4% 0.73 
Angiotensin II receptor blockers 4.0% 4.7% 0.74 11.0% 10.6% 0.91 
Stroke/Bleeding Risk       
CHADS2, mean (SD) 2.6 (1.1) 2.6 (1.2) 0.93 2.6 (2.5) 2.7 (2.5) 0.46 
CHA2DS2-VASc, mean (SD) 4.4 (1.4) 4.5 (1.6) 0.89 4.4 (1.5) 4.6 (1.6) 0.28 
ATRIA stroke risk score, mean 
(SD) 
7.6 (2.3) 7.7 (2.5) 0.67 7.1 (2.3) 7.5 (2.4) 0.07 
HAS-BLED, mean (SD) * 2.3 (1.0) 2.8 (1.0) <0.001 2.6 (0.9) 3.0 (0.9) <0.001 
ATRIA hemorrhage risk score, 
mean (SD) 
4.3 (2.4) 4.6 (2.3) 0.12 4.4 (2.0) 5.0 (2.1) 0.01 
* The HAS-BLED score presented here has a maximum of 7 points since data on alcohol usage was not available and time in 
therapeutic range was not included. If adding 1 point for time in therapeutic range < 60%, there is no significant difference 
between those using and not using warfarin. 
† All cancer excluding non-melanomatous skin cancer 
‡ Female: hemoglobin < 13.5 g/L; Male: hemoglobin < 12.0 g/L 
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Table 1.2 – Association between warfarin usage at the time of major GI 
hemorrhage and 30-day mortality in the ATRIA and ATRIA-CVRN cohorts 
 
 ATRIA ATRIA-CVRN 
 Warfarin No Warfarin Warfarin No Warfarin  
30-day Mortality n=223 n=191 n=210 n=151 
    Deaths, n (%)  25 (11.2%) 25 (13.1%) 10 (4.8%) 21 (14.0%) 
    Person-years 16.8 14.0 16.3 11.2 
    Rate Ratio (unadjusted) 
0.84  
(0.48–1.46) 
- 
0.33  
(0.16–0.70) 
- 
    Rate Ratio (adjusted) † 
0.97  
(0.54–1.74) 
- 
0.37  
(0.17–0.81) 
- 
† Variables included in propensity score, ATRIA: age, race/ethnicity, low educational 
attainment, low annual household income, smoking status, history of mechanical falls, prior 
ischemic stroke, diabetes mellitus, coronary disease, hypertension, chronic heart failure, 
dementia, significant kidney dysfunction, systemic cancer, use of other antiplatelet therapies, 
lipid-lowering agents, and ACE inhibitors;  ATRIA-CVRN: age, race/ethnicity, gender, low 
educational attainment, low annual household income, smoking status, history of GI 
hemorrhage, prior ischemic stroke, diabetes mellitus, coronary disease, hypertension, 
chronic heart failure, dementia, chronic liver disease, significant kidney dysfunction, anemia, 
lung disease, transient ischemic attack, use of antiplatelets, lipid-lowering agents, ACE 
inhibitors, angiotensin II receptor blockers. 
 
Table 1.3 – Association between warfarin usage at the time of major GI 
hemorrhage and long-term mortality in the ATRIA and ATRIA-CVRN cohorts 
 
 ATRIA ATRIA-CVRN 
 Warfarin No Warfarin Warfarin No Warfarin  
Long-term mortality n=223 n=191 n=210 n=151 
    Deaths, n (%) 66 (29.6%) 80 (41.9%) 34 (16.2%) 36 (23.8%) 
    Person-years 162.4 127.7 140.1 83.9 
    Rate Ratio (unadjusted) 
0.66 
 (0.48–0.92) 
- 
0.61    (0.38–
0.97) 
- 
    Rate Ratio (adjusted) † 
0.76  
(0.54–1.07) 
- 
0.69    (0.42–
1.13) 
- 
† Variables included in propensity score, ATRIA: age, race, gender, low educational 
attainment, smoking status, history of coronary disease, chronic heart failure, dementia, 
significant kidney dysfunction, systemic cancer, anemia, use of other antiplatelet therapies, 
lipid-lowering agents, ACE inhibitors, and angiotensin II receptor blockers; ATRIA-CVRN: 
age, race/ethnicity, gender, low educational attainment, smoking status, history of 
mechanical falls, prior GI hemorrhage, ischemic stroke, diabetes mellitus, coronary disease, 
hypertension, chronic heart failure, dementia, chronic liver disease, significant kidney 
dysfunction, systemic cancer, anemia, lung disease, use of aspirin, antiplatelets, lipid-
lowering agents, ACE inhibitors, and angiotensin II receptor blockers. 
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Table 1.4 – Association between warfarin usage at the time of major GI 
hemorrhage and 30-day and long-term mortality with adjustment by finely divided 
propensity score strata 
 
 ATRIA ATRIA-CVRN 
30-day Mortality   
    Adjusted mRR (8 strata) 0.94 (0.53–1.68) 0.35 (0.15–0.79) 
    Adjusted mRR (10 strata) 0.88 (0.49–1.59) 0.38 (0.17–0.86) 
Long-term Mortality   
    Adjusted mRR (8 strata) 0.75 (0.54–1.06) 0.68 (0.41–1.12) 
    Adjusted mRR (10 strata) 0.77 (0.54–1.08) 0.68 (0.41–1.13) 
 
Table 1.5 – Attributes of an unknown confounder, which would be required to 
convert the observed association in the ATRIA-CVRN cohort for 30-day mortality 
to a null association 
 
Prevalence of 
Confounder Among 
Warfarin Users 
Prevalence of 
Confounder Among 
Warfarin Non-Users 
Rate Ratio for 
Confounder/Mortality 
Association 
Modified Mortality 
Rate Ratio for 
Warfarin/Mortality 
Association 
90% 20% 3.50 0.96 
80% 10% 3.00 0.96 
90% 10% 3.50 1.05 
90% 20% 3.75 1.05 
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Figure 1.1a - Adjusted survival function for the association between 
warfarin and 30-day mortality in the ATRIA cohort 
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Figure 1.1b – Adjusted survival function for the association between 
warfarin and 30-day mortality in the ATRIA-CVRN cohort 
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Figure 1.2a – Adjusted survival function for the association between 
warfarin and 1-year mortality in the ATRIA cohort 
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Figure 1.2b: Adjusted survival function for the association between 
warfarin and 1-year mortality in the ATRIA-CVRN cohort 
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IMPACT OF DURATION OF DIABETES AND GLYCEMIC CONTROL ON 
ISCHEMIC STROKE RISK IN PATIENTS WITH ATRIAL FIBRILLATION 
 
BACKGROUND 
Atrial fibrillation (AF) is the most common clinically significant arrhythmia 
and is associated with a 4- to 5-fold increase in the risk for ischemic stroke.4, 6 
Roughly fifteen percent of patients with AF also carry the diagnosis of diabetes.9, 
48 Diagnosed diabetes mellitus is a consistently documented risk factor for 
ischemic stroke in patients with AF.15, 49 A diagnosis of diabetes is included in the 
CHADS2 (Congestive heart failure, Hypertension, Age, Diabetes, Prior Stroke) 
and CHA2DS2-VASc stroke risk scoring systems for AF patients that are widely 
used to guide decision making for anticoagulation therapy.26, 34 However, it is 
unclear which aspects of diabetes, including duration and glycemic control, may 
be associated with an increased risk of stroke in AF patients as prior studies 
have only assessed the diagnosis of diabetes as a risk factor.15, 49 
 The association between duration of type 2 diabetes and ischemic stroke 
risk has recently been studied in a general population of patients, with longer 
duration of diabetes associated with increased risk of stroke compared to non-
diabetic patients.50, 51 The association between hemoglobin A1c (HbA1c), a 
measure of glycemia during the prior 3 months, and ischemic stroke among 
patients with diabetes has been investigated in general populations.52–54 Elevated 
HbA1c at baseline was an independent risk factor for stroke in patients with 
diabetes with risk ratios of 1.17 and 2.33 for the highest two tertiles of HbA1c 
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compared with the lowest tertile over 10 years of follow-up.53 Despite evidence 
for an association between elevated HbA1c and duration of diabetes with excess 
risks of stroke among diabetics in general, predominantly non-AF populations, it 
is unknown whether there is an association among diabetic patients with AF 
since the pathophysiology of stroke may be different in these populations.  
 To address these knowledge gaps, we aimed to assess the association 
between duration of diabetes and glycemic control with the rate of ischemic 
stroke in AF patients off anticoagulation therapy in clinical care within a large 
community-based cohort of patients with AF and comprehensive follow-up. 
 
METHODS 
Source Population 
Assembly of the Anticoagulation and Risk Factors in Atrial fibrillation 
(ATRIA) cohort was described in Study 1. In brief, the cohort includes 13,559 
adults aged 18 and older with diagnosed non-valvular AF who received care with 
Kaiser Permanente (KP) Northern California.9 Cohort members were identified by 
searching electronic inpatient, outpatient, and electrocardiographic databases for 
physician-assigned International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9) diagnostic codes of AF (427.31, 427.32) between 
July 1996 and December 1997. We included all patients ≥ 18 years old with 
either 2 or more outpatient AF diagnoses or 1 outpatient AF diagnosis with 
electrocardiogram (ECG) validation. Included patients were followed through 
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September 2003.  Since we were interested in non-transient, nonvalvular AF, we 
excluded AF patients with diagnosed mitral stenosis, valvular repair or 
replacement, transient postoperative AF, or concurrent hyperthyroidism.  
 We focused these analyses on patients with diagnosed diabetes mellitus 
at baseline or who were diagnosed during follow-up. The presence of diabetes 
mellitus was assessed from a validated longitudinal regional health plan diabetes 
registry4, 55 which used relevant inpatient and outpatient diagnoses (ICD-9 250.0 
– 250.8), an abnormal (>6.7%) hemoglobin A1c (HbA1c) level, or a filled 
prescription for oral hypoglycemic agents or insulin to identify patients with 
diabetes. The patient’s index date for these analyses was either the beginning of 
follow-up in the ATRIA cohort for those with diabetes at baseline, or the date of 
diabetes onset for those diagnosed with diabetes during follow-up in the ATRIA 
cohort. 
Definitions of variables 
 Duration of diabetes was assigned as a time-varying exposure and 
categorized as < 3 years and ≥ 3 years. A three-level categorization was initially 
explored (<3, 3–8, >8 years), but the longer duration categories were collapsed 
due to similar effect sizes (Appendix 5). For analyses among diabetics, duration 
<3 years was considered as the reference category. We conducted additional 
analyses where AF patients without diabetes were considered as the reference 
category. Diabetes onset date for duration calculations was determined based on 
information either by self-report from respondents with diabetes from the 
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diabetes registry or by using information based on meeting the first qualifying 
criteria from diagnoses, laboratory test results or medications. Patients without a 
diabetes onset date were excluded (n=106) from all analyses.  
Glycemic control was measured with HbA1c values from the regional 
health plan laboratory database based on HbA1c tests that were ordered as part 
of clinical management. HbA1c values were updated over time, and were 
considered valid for up to 1-year. At baseline, we looked back over the prior year 
for the most recent HbA1c value. If there was no value during this time period, 
the time between baseline and the first HbA1c value after baseline was excluded. 
If this time period between baseline and the first HbA1c value was longer than 1 
year, then the patient was excluded from analysis since a large proportion of their 
person-time was excluded due to missing HbA1c values and there was some 
doubt if they truly had diabetes (see Results section) (n=171). If the time between 
HbA1c values during follow-up exceeded 1-year, then the time from 1-year 
follow-up until the next HbA1c value was excluded. HbA1c values were 
categorized at common clinical cut points of: <7.0%, 7.0% – 9.0%, and >9.0%. 
We also performed a sensitivity analysis regarding the missing HbA1c values, 
where HbA1c values were considered valid for only 6-months, for up to 1.5 
years, and where values were assigned using linear interpolation between 
HbA1c tests. 
 The outcome of interest was ischemic stroke, which was identified by 
searching hospitalization and billing claims databases for relevant ICD-9 codes 
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for ischemic stroke found in the primary discharge diagnosis position.9 Potential 
events were adjudicated by two physician members of a Clinical Outcomes 
Committee using medical records review, with a final decision made by a 
consulting neurologist if consensus was not reached by the committee. A valid 
ischemic stroke was defined as a documented acute neurological deficit lasting > 
24 hours that was not explained by other causes (e.g., primary hemorrhage, 
trauma, infection, or vasculitis).  
To examine the role of glycemic control and duration of diabetes on risk of 
ischemic stroke, we focused on periods of follow-up off anticoagulation. To 
identify periods off warfarin therapy, we used a previously validated method to 
assign use of warfarin based on data from prescriptions and outpatient 
international normalized ratio measurements found in pharmacy and laboratory 
databases, respectively.9 Longitudinal warfarin exposure was based on number 
of days of supply per prescription and intervening international normalized ratios. 
For any 2 consecutive prescriptions with a gap of up to 60 days, a patient was 
considered to be continuously on warfarin. For gaps >60 days, we considered the 
patient to be continuously on warfarin if there was intervening international 
normalized ratio measurements at least every 42 days. Otherwise, the patient 
was considered off warfarin from day 31 after the end date of the first prescription 
until the start date of the next prescription. This grace period of 30 days at the 
end of each warfarin period was given because changes in warfarin dose in 
response to International normalized ratio (INR) test results are common.  
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Patient characteristics, including data on patient age (continuous), gender, 
and self-reported race/ethnicity (white, black/African American, Asian/Pacific 
Islander, Hispanic ethnicity, other/unknown) were obtained from administrative 
databases. History of comorbid conditions, including prior ischemic stroke, 
chronic heart failure, coronary disease, and hypertension, were collected from 
clinical inpatient and ambulatory databases using validated algorithms and were 
assessed using data during the five years prior to the patient’s index date. Kidney 
dysfunction (defined as estimated glomerular filtration rate [eGFR] < 45 
ml/min/1.73 m2) was calculated from laboratory values using the Chronic Kidney 
Disease Epidemiology (CKD-EPI) Collaboration formula 33. Patients without an 
eGFR value in the prior year were considered to have normal renal function and 
patients on dialysis were considered to have kidney dysfunction.  Proteinuria was 
defined as a urine dipstick protein result of ≥1+ (30 mg/dL or higher) in the 
absence of potential urinary tract infection found in laboratory databases.56 
Patients without a urine dipstick protein laboratory result in the prior year were 
considered to not have proteinuria. Insulin use was time-varying and assessed 
from prescription databases. All health-related variables were dichotomized. For 
all patients, the CHADS2,26 CHA2DS2-VASc,34 and ATRIA35 stroke risk scores 
were calculated. 
Statistical analysis 
We conducted descriptive and stratified analyses to examine the 
distribution of potential confounders among duration and HbA1c categories. The 
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associations between comorbid conditions and diabetes characteristics with 
duration and HbA1c categories were adjusted for age, gender, and race in 
logistic regression models. To construct person-time data, follow-up began on 
the first day the patient held a diagnosis of diabetes and was not receiving 
warfarin therapy and ended at the first occurrence of any of the following: 
ischemic stroke, death, disenrollment from the health plan, or end of the follow-
up period. Cox proportional hazards regression was used to estimate the 
unadjusted, minimally adjusted (age, gender, race), and fully adjusted hazard 
ratio (HR) for the association between HbA1c and ischemic stroke, as well as 
with duration of diabetes and ischemic stroke (SAS, version 9.3 [SAS Institute, 
Cary, North Carolina]). To further assess and control for confounding, we added 
CHA2DS2-VASc (which includes all the CHADS2 risk factors) and ATRIA stroke 
risk score factors to our multivariable models. For the HbA1c analysis, we also 
adjusted for time-varying use of insulin and duration of diabetes. For the duration 
of diabetes analyses, we did not adjust for HbA1c, use of insulin, proteinuria, or 
kidney dysfunction since we believed these variables to be on the causal 
pathway from diabetes duration to ischemic stroke. Duration analyses were 
stratified by age (<75 years and ≥ 75 years). All analyses were conducted only 
among patients with prevalent diabetes at baseline. To assess the presence of 
additive interaction between HbA1c and diabetes duration, we calculated the 
relative excess rate due to interdependence (RERI).57 
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RESULTS 
Characteristics of the study population 
 
Patients with no HbA1c value to use at the start of the study (i.e. no 
HbA1c in the 1-year before the subject’s index date, and no HbA1c value in the 
1-year after the index date) were compared to patients who did not have such a 
gap in HbA1c measures (Table 2.1). The subjects with a large gap in HbA1c 
measures were more likely to have HbA1c < 7.0% and had a lower rate of 
ischemic stroke. Additionally, these patients were less likely to use insulin and 
had a shorter duration of diabetes. These subjects also had a very large 
proportion of their person-time (48%) excluded due to this initial gap in HbA1c 
measures. We elected to exclude these subjects (n=171) for these reasons, and 
because there is some doubt as to whether they truly hold a diagnosis of 
diabetes. Table 2.2 compares patients (after excluding n=171 from Table 2.1) 
who have all HbA1c measures within 1-year of each other and patients who have 
at least one instance where the time between HbA1c measures was > 1-year. 
Subjects with a gap < 1 year were slightly less likely to have HbA1c values under 
7, however they had significantly higher rates of ischemic stroke compared to 
those with a gap > 1 year during follow-up. There was little difference between 
these two groups in other covariables. Based on this table, we were comfortable 
with the method of using HbA1c values for up to 1-year. Although having a gap 
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during follow-up was strongly associated with the outcome of ischemic stroke, it 
was not associated with exposure, so not expected to cause bias. 
Among 2101 diabetic patients included in the diabetes duration analysis, 
837 (39.8%) had estimated diabetes duration for ≤ 3 years at baseline, while 
1264 (60.2%) had estimated diabetes duration for > 3 years at baseline (Table 
2.3). The mean duration of diabetes at baseline was 7.5 years (SD: 9.6, Median: 
4.7).  Patients who had diabetes for > 3 years were older than those with 
diabetes for 0–3 years. In addition, they were more likely to have had a prior 
ischemic stroke, to have diagnosed chronic heart failure, coronary disease, 
peripheral arterial disease, hypertension, proteinuria, significant kidney 
dysfunction, to be using insulin, and to have HbA1c ≥ 9.0% compared to patients 
with duration ≤ 3 years at baseline after adjusting for age, gender, and race. 
Patients with longer duration of diabetes also had higher CHADS2, CHA2DS2-
Vasc, and ATRIA stroke risk scores.  
Among 1933 diabetic patients included in the HbA1c analysis, 883 
(45.7%) had a HbA1c value <7.0% at baseline, while 690 (35.7%) had a HbA1c 
value between 7.0 and 8.9%, and 360 (18.6%) had a HbA1c value ≥ 9.0% (Table 
2.3). Patients with HbA1c ≥ 9.0% were younger and less likely to be white. 
Patients with HbA1c ≥ 9.0% were also less likely to have diagnosed 
hypertension, were more likely to be using insulin, and had diabetes for a longer 
period of time compared to patients with lower HbA1c values at baseline after 
adjusting for age, gender, and race. There were small, but statistically significant, 
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differences in CHADS2, CHA2DS2-Vasc, and ATRIA stroke risk scores among 
HbA1c categories, with HbA1c ≥ 9.0% having the lowest stroke risk scores.  
Follow-up 
In the duration of diabetes analysis, there was 5219.7 person-years off of 
warfarin therapy included (mean [SD]: 2.48 [2.23] years per patient) among 
diabetics. Non-diabetics contributed 25,806.7 person-years off warfarin therapy 
(mean [SD]: 3.09 [2.48] years per patient). For both analyses, diabetic patients 
without a known diabetes onset date were excluded, but they only represented 
102.2 person-years. 
There were a total of 7217 HbA1c measurements during follow-up. The 
median number of days between HbA1c measurements was 143 (interquartile 
range 89–240) days, with median 154 days among HbA1c < 7.0% group; median 
135 days among HbA1c 7.0%–8.9%; and median 135 days among HbA1c ≥ 
9.0%). The HbA1c analysis included 3818.0 person-years off of warfarin therapy 
(mean [SD]: 1.98 [1.98] years per patient). Due to gaps between HbA1c 
measures that exceeded 1-year, 1236.8 person-years off-warfarin were excluded 
from analysis.  
Duration of diabetes and ischemic stroke 
During follow-up, there were 137 validated ischemic stroke events among 
diabetics included in the duration of diabetes analysis. The rate of ischemic 
stroke during follow-up was higher among patients with estimated duration of 
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diabetes ≥ 3 years (2.9/100 person-years) compared with patients who had an 
estimated duration of diabetes less than 3 years (1.7/100 person-years) (Table 
2.4). In unadjusted analyses, diabetes duration ≥ 3 years was associated with an 
increased rate of ischemic stroke compared with duration < 3 years (unadjusted 
HR: 2.04, 95% CI: 1.27–3.26). After adjustment for stroke risk factors in 
multivariable analyses, the increased rate of ischemic stroke associated with 
diabetes duration ≥ 3 years remained elevated (adjusted HR: 1.75, 95% CI: 
1.05–2.90). In analyses stratified by age (<75 and ≥75 years), the increased rate 
of ischemic stroke in patients with duration ≥ 3 years was present in both age 
groups, but was larger in the older age group (<75 years – adjusted HR: 1.42, 
95% CI: 0.73–2.75; ≥75 years – adjusted HR: 2.26, 95% CI: 1.02–4.98) (Table 
2.5). Additive interaction between duration and age was small and not statistically 
significant (RERI: 0.34, 95% CI: -0.57–1.24). Since subjects with a prior stroke 
may be at increased risk of incident ischemic stroke, we performed analyses 
(both unstratified and stratified by age), which excluded those with prior ischemic 
stroke and results were similar (data not shown). Compared with non-diabetics, 
diabetics with an estimated duration > 3 years had an increased rate of ischemic 
stroke (adjusted HR: 1.62, 95% CI: 1.31–2.01), while diabetics with a duration < 
3 years did not (adjusted HR: 0.90, 95% CI: 0.58–1.40) (Table 2.4). Most 
ischemic stroke events among diabetics occurred among those with diabetes at 
baseline (116 of 137 ischemic stroke events). Analyses restricted to diabetics 
with prevalent diabetes compared to non-diabetics were similar to analyses that 
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included patients with prevalent and incident diabetes (Appendix 6).  
HbA1c and ischemic stroke 
During follow-up, there were 104 validated ischemic stroke events 
included in the HbA1c analysis. The rate of ischemic stroke during follow-up was 
2.7/100 person-years (unadjusted hazard ratio (HR): 1.11, 95% CI: 0.63–1.98) in 
patients with HbA1c ≥ 9.0%, 3.0/100 person-years (unadjusted HR: 1.22, 95% 
CI: 0.80–1.87) in patients with HbA1c between 7.0% and 8.9%, compared to a 
rate of 2.5/100 person-years in patients with HbA1c < 7.0% (Table 2.6). In 
multivariable models adjusting for stroke risk factors, insulin use, and diabetes 
duration, neither poor glycemic control (HbA1c ≥ 9.0%, adjusted HR: 1.04, 95% 
CI: 0.57–1.91) or moderately increased HbA1c (7.0%–8.9%, adjusted HR: 1.17, 
95% CI: 0.75–1.82) were significantly associated with an increased rate of 
ischemic stroke compared with patients who had HbA1c < 7.0%. Results were 
similar when using different rules for classifying time-varying HbA1c values (i.e. 
valid for 6 months, valid for 1.5 years, and assessed using linear interpolation) 
(Table 2.7). Since the rate of ischemic stroke did not vary by HbA1c level among 
diabetics, we do not present analyses with non-diabetics as the reference group. 
Most ischemic stroke events occurred in diabetic patients who had diabetes at 
baseline (91 of 104 ischemic stroke events). Analyses restricted to patients who 
had diabetes at baseline were similar to those that included patients with 
prevalent and incident diabetes (Appendix 7). 
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Interaction between Hba1c and duration of diabetes 
Among diabetics, additive interaction between HbA1c and duration of 
diabetes was assessed with HbA1c dichotomized at both 7.0% (RERI: 0.05, 95% 
CI: -1.00–1.09) and 9.0% (RERI: -0.35, 95% CI: -2.19–1.49) and in both cases 
the magnitude of interaction was small. 
 
DISCUSSION 
Within a large, ambulatory cohort of adults with atrial fibrillation and 
diabetes, we found that longer estimated duration of diabetes was strongly 
associated with an increase in adjusted rate of ischemic stroke, while elevated 
hemoglobin A1c values were not significantly associated with an increase in 
ischemic stroke among diabetics. The increased rate of ischemic stroke in those 
who have had diabetes for an estimated 3 or more years appeared to be 
independent of age as the association was present in both older (≥75 years) and 
younger (<75 years) subjects. 
 Our results for diabetes duration are consistent with prior research 
conducted within a general population of patients which found an increased rate 
of ischemic stroke as duration increased compared to non-diabetic patients.50, 51 
However, our results for HbA1c in diabetics with AF are not consistent with prior 
research conducted in diabetics in general. In our study, increased HbA1c did not 
have a substantial impact on the rate of ischemic stroke, while elevated HbA1c 
was significantly associated with ischemic stroke in predominantly non-AF 
populations.52–54 A potential reason for HbA1c having no association with 
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ischemic stroke in diabetic patients with AF is the difference in the primary 
mechanism for stroke in diabetic patients with and without AF. Among patients 
with diabetes who do not have AF, stroke is primarily due to underlying 
atherosclerosis.58, 59 This mechanism may not be as important among diabetic 
patients with AF since the primary mechanism for ischemic stroke is atrio-
embolic.60 Duration of diabetes may be most important among AF populations 
due to enhanced thrombin generation, impaired fibrinolysis with prolonged lysis 
time, and unfavorably altered plasma fibrin clot structure which may increase the 
risk of thrombotic events.61, 62 
 Current stroke risk scoring systems for AF patients include a diagnosis of 
diabetes mellitus as a stroke risk factor.26, 34, 35 While the diagnosis of diabetes 
has been shown to be a risk factor for stroke, the magnitude of this association 
has varied among different studies and has often been quite small. For example, 
the association between diabetes and stroke was small in the Swedish Atrial 
Fibrillation cohort study (adjusted HR: 1.19) and the UK General Practice 
Research Database (adjusted incidence rate ratio (IRR): 1.33), while the 
association was larger in the ATRIA (HR: 1.57) and the AF Investigators pooled 
analyses of warfarin trials (IRR=1.7).35, 48, 63, 64 Our study demonstrates that 
stroke risk schemes for AF patients could be improved by accounting for how 
long a patient has had diabetes. 
 This study was strengthened by including a large number of AF patients 
with diabetes from a community-based cohort with comprehensive follow-up. The 
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registry we utilized to identify patients with diabetes has been demonstrated to be 
highly sensitive (96% with self-reported diabetes from survey as gold standard) 
and specific (2% false positives).55 All events were adjudicated by physicians or 
nurses using a standardized medical record review protocol that minimizes errors 
in case ascertainment. For both HbA1c and diabetes duration, we also were able 
to consider these variables as time-varying to minimize misclassification when 
assessing their association with ischemic stroke.  
 This study has several potential limitations. We are unable to separate 
type 1 and type 2 diabetes. However, given the age of onset in this population 
and the prevalence of type 2 diabetes, we expect the vast majority are type 2 
diabetics. As this was a clinical practice-derived cohort, there was no structured 
protocol to screen for diabetes, so there may be some misclassification about the 
actual duration of diabetes, especially given that there is often a lag between 
diabetes onset and diagnosis.65 Although this study improves upon prior studies 
by analyzing repeated measures of HbA1c, it is possible that misclassification 
and/or selection bias may have occurred. Since not all patients received 
regularly-spaced HbA1c lab monitoring, our primary analyses allowed an HbA1c 
value to be valid for up to 1-year. This approach was meant to minimize 
misclassification by using a single HbA1c value for an extended period of time.  
We examined the potential for selection bias by comparing patients who did 
versus did not go more than 1-year between HbA1c measurements and found 
having a gap between HbA1c measures of ≥ 1-year was not associated with 
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HbA1c value, which alleviated concerns about selection bias with this approach. 
Additionally, we performed several sensitivity analyses using different 
approaches for handling time-varying HbA1c values. Considering a HbA1c value 
valid for 6-months, 18-months, and using a linear interpolation approach (which 
did not exclude person-time based on gaps in measurements) all had similar 
results to our primary approach. It is possible that there is residual confounding in 
these analyses. Confounding by age was of particular concern since increased 
duration is correlated with increased age. In addition to controlling for age in our 
multivariable models, we also stratified our duration analyses by age and found 
that duration of diabetes was associated with ischemic stroke in both younger 
and older patients, although was only statistically significant in older patients due 
to wide confidence intervals. 
In conclusion, our study demonstrates that duration of diabetes is a more 
important predictor of ischemic stroke than glycemic control in patients who have 
both diabetes and atrial fibrillation. Given the relatively small association between 
the diagnosis of diabetes and ischemic stroke in several published studies, 
accounting for duration of diabetes may improve stroke risk models for patients 
with atrial fibrillation. 
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Table 2.1: ATRIA participants who have no initial gap or ≤ 1 year gap in HbA1c 
measures at the start of follow-up and those who have an initial gap of > 1 year 
 
 No initial gap, or initial gap 
≤ 1 year 
(n=1933) 
Initial gap > 1 year 
(n=171) 
P-value 
HbA1c value at baseline:    
A1c < 7 883 (45.7%) 91 (53.2%) 0.02 
A1c 7–9 690 (35.7%) 42 (24.6%)  
A1c ≥ 9 360 (18.6%) 38 (22.2%)  
Ischemic stroke 
(events/person year) 
(104/3818.0 years)    
0.0273 / person-year 
(6/347.1 years) 
0.0173 / person-year 
0.27 
Covariables    
Race, white 1638 (84.7%) 133 (77.8%) 0.03 
Insulin use 517 (26.7%) 34 (19.9%) 0.02 
Duration of diabetes   0.01 
    0–3 years 773 (40.0%) 85 (49.7%)  
    > 3 years 1160 (60.0%) 86 (50.3%)  
 
Table 2.2: ATRIA participants who do and do not have a gap of > 1 year between 
HbA1c measures during follow-up  
 
 ≤ 1 year between all 
HbA1c measures 
(n=1108) 
> 1 year between 
HbA1c measures 
(n=825) 
P-value 
HbA1c value at baseline:    
A1c < 7 502 (45.3%) 381 (46.2%) 0.34 
A1c 7–9 409 (36.9%) 281 (34.1%)  
A1c ≥ 9 197 (17.8%) 163 (19.8%)  
Ischemic stroke 
(events/person-year) 
(75/1465 years) 
0.0512 / person-year 
(29/2353 years) 
0.0123 / person-year 
<0.001 
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Table 2.3: Characteristics of diabetic patients by estimated diabetes duration and HbA1c values at baseline 
 
  Diabetes Duration‡ HbA1c* 
 Non-
Diabetic 
(n=8356) 
0–3 years 
(n=837) 
≥3 years 
(n=1264) 
P-
Value§ 
HbA1c < 
7.0% 
(n=835) 
HbA1c 7.0–
8.9% 
(n=652) 
HbA1c ≥ 
9.0% 
(n=340) 
P-
Value§ 
Age, mean (SD), years 71.8 (12.7) 69.0 (11.0) 71.7 (8.9) <0.001 71.5 (9.6) 70.5 (9.7) 67.9 (9.8) <0.001 
    <65 1903 (22.8%) 244 (29.2%) 251 (19.9%) <0.001 184 (20.8%) 161 (23.3%) 118 (32.8%) <0.001 
    65–74 2422 (29.0%) 311 (37.2%) 494 (39.1%)  326 (36.9%) 277 (40.1%) 144 (40.0%)  
    ≥ 75 4031 (48.2%) 282 (33.7%) 519 (41.1%)  374 (42.4%) 252 (36.5%) 98 (27.2%)  
Gender, female 3714 (44.5%) 321 (38.4%) 501 (39.6%) 0.55 325 (36.8%) 273 (39.6%) 153 (42.5%) 0.16 
Race    <0.001    0.02 
    White 7226 (86.5%) 700 (83.6%) 1071 (84.7%)  764 (86.5%) 591 (85.7%) 283 (78.6%)  
    Black/African American 306 (3.7%) 28 (3.4%) 73 (5.8%)  31 (3.5%) 35 (5.1%) 28 (7.8%)  
    Asian/Pacific Islander 416 (5.0%) 75 (9.0%) 74 (5.9%)  55 (6.2%) 44 (6.4%) 33 (9.2%)  
    Hispanic 193 (2.3%) 23 (2.8%) 43 (3.4%)  27 (3.1%) 15 (2.2%) 14 (3.9%)  
    Other/Unknown 215 (2.6%) 11 (1.3%) 3 (0.2%)  6 (0.7%) 4 (0.6%) 3 (0.8%)  
Comorbidities and 
Diabetes Characteristics 
        
Prior ischemic stroke 632 (7.6%) 52 (6.2%) 173 (13.7%) <0.001
†
 92 (10.4%) 70 (10.1%) 35 (9.7%) 0.98
†
 
Chronic heart failure 2141 (25.6%) 251 (30.0%) 583 (46.1%) <0.001
†
 342 (38.7%) 264 (38.3%) 146 (40.6%) 0.36
†
 
Coronary disease 2117 (25.3%) 261 (31.2%) 581 (46.0%) <0.001
†
 351 (39.8%) 287 (41.6%) 134 (37.2%) 0.56
†
 
Peripheral arterial disease 157 (1.9%) 18 (2.2%) 63 (5.0%) 0.005
†
 34 (3.9%) 26 (3.8%) 14 (3.9%) 0.86
†
 
Hypertension 3852 (46.1%) 497 (59.4%) 901 (71.3%) <0.001
†
 601 (68.1%) 475 (68.8%) 220 (61.1%) 0.02
†
 
Proteinuria 926 (11.1%) 103 (12.3%) 366 (29.0%) <0.001
†
 185 (21.0%) 146 (21.2%) 91 (25.3%) 0.26
†
 
Significant kidney 
dysfunction 
1166 (14.0%) 94 (11.2%) 280 (22.2%) <0.001
†
 150 (17.0%) 119 (17.2%) 58 (16.1%) 0.92
†
 
Insulin use - 38 (4.5%) 490 (38.8%) <0.001
†
 142 (16.1%) 226 (32.8%) 149 (41.4%) <0.001
†
 
HbA1c Value    <0.001
†
     
    < 7.0% - 417 (49.8%) 461 (36.5%)  - - -  
    7.0–8.9% - 285 (34.1%) 508 (40.2%)  - - -  
    ≥9.0% - 135 (16.1%) 295 (23.3%)  - - -  
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Duration of diabetes        <0.001
†
 
    0–3 years - - -  458 (51.9%) 226 (32.8%) 89 (24.7%)  
    ≥3 years - - -  425 (48.1%) 464 (67.2%) 271 (75.3%)  
Predicted Stroke Risk         
CHADS2, mean (SD) 1.4 (1.1) 2.4 (1.1) 2.9 (1.2) <0.001 2.7 (1.2) 2.6 (1.1) 2.5 (1.0) 0.01 
CHA2DS2-VASc, mean (SD) 2.8 (1.7) 3.8 (1.6) 4.5 (1.6) <0.001 4.3 (1.6) 4.2 (1.6) 4.0 (1.6) 0.01 
ATRIA stroke risk score, 
mean (SD) 
4.9 (2.8) 5.5 (2.7) 6.8 (2.6) <0.001 6.4 (2.7) 6.2 (2.6) 5.8 (2.7) 0.008 
* Population excludes n=171 with initial gap > 1 year and n=106 without a diabetes onset date (n=274 total) 
‡ Population excludes n=106 without a diabetes onset date 
†Adjusted for age, gender, race 
§P-Values represent comparisons among diabetic patients (Reference categories are duration ≤ 3 years and HbA1c < 7%). Compared to 
non-diabetic patients, diabetics with duration ≤ 3 years were significantly different (p<0.05) in all categories except for peripheral arterial 
disease, prior ischemic stroke, and significant kidney dysfunction. Diabetics with duration > 3 years were significantly different in all 
categories except mean age. 
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Table 2.4: Association between estimated duration of diabetes and incidence of 
ischemic stroke 
 
 Non-Diabetic Estimated 
Diabetes 
Duration < 3 
years 
Estimated 
Diabetes 
Duration ≥3 
years 
    
    Ischemic stroke events 463 21 116 
    Person-years 25,801.8 1260.6 3959.1 
    Rate 1.8/100 person-
years 
1.7/100 person-
years 
2.9/100 person-
years 
Among Diabetics Only    
    Hazard Ratio (unadjusted) n/a Reference 2.04 (1.27–3.26) 
    Hazard Ratio (minimally adjusted*) n/a Reference 1.88 (1.14–3.13) 
    Hazard Ratio (adjusted‡) n/a Reference 1.75 (1.05–2.90) 
Among All Patients    
    Hazard Ratio (unadjusted) Reference 0.84 (0.55–1.30) 1.75 (1.43–2.15) 
    Hazard Ratio (minimally adjusted*) Reference 0.97 (0.63–1.50) 1.92 (1.56–2.36) 
    Hazard Ratio (adjusted‡) Reference 0.90 (0.58–1.40) 1.62 (1.31–2.01) 
* Adjusted for age, gender, and race 
‡ Adjusted for age, gender, race, congestive heart failure, hypertension, prior ischemic stroke, 
coronary artery disease, and peripheral arterial disease 
 
 
Table 2.5: Association between estimated duration of diabetes and incidence of 
ischemic stroke stratified by age (<75 years and ≥ 75 years) 
 
 Duration < 3 years Duration ≥3 years 
Age < 75   
    Ischemic stroke events 12 56 
    Person-years 856.6 2537.8 
    Rate 1.4/100 person-years 2.2/100 person-years 
    Hazard Ratio (unadjusted) - 1.78 (0.95–3.33) 
    Hazard Ratio (adjusted*) - 1.51 (0.80–2.85) 
   
Age ≥ 75   
    Ischemic stroke events 9 60 
    Person-years 403.9 1421.2 
    Rate 2.2/100 person-years 4.2/100 person-years 
    Hazard Ratio (unadjusted) - 2.14 (1.05–4.39) 
    Hazard Ratio (adjusted*) - 2.14 (1.05–4.35) 
* Adjusted for age, gender, race, congestive heart failure, hypertension, prior stroke, coronary 
artery disease, and peripheral arterial disease 
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Table 2.6 – Association between time-varying HbA1c values and incidence of 
ischemic stroke 
 
 HbA1c < 7.0% HbA1c 7.0–8.9% HbA1c ≥ 9.0% 
    Ischemic stroke events 42 46 16 
    Person-years 1690.8 1545.3 581.9 
    Rate 2.5/100 person-
years 
3.0/100 person-
years 
2.7/100 person-
years 
    Hazard Ratio (unadjusted) Reference 1.22 (0.80–1.87) 1.11 (0.63–1.98) 
    Hazard Ratio (minimally adjusted*) Reference 1.30 (0.85–1.99) 1.27 (0.72–2.24) 
    Hazard Ratio (adjusted‡) Reference 1.17 (0.75–1.82) 1.04 (0.57–1.91) 
* Adjusted for age, gender, and race 
‡ Adjusted for age, gender, race, congestive heart failure, hypertension, prior ischemic stroke, 
coronary artery disease, peripheral arterial disease, proteinuria, significant kidney dysfunction, 
insulin use, and diabetes duration 
 
 
Table 2.7: Association between time-varying HbA1c values and incidence of 
ischemic stroke using different rules for classifying time-varying HbA1c values 
(i.e. valid for 6-months, valid for 1.5 years, and assessed using linear 
interpolation) 
 
 HbA1c < 7.0% HbA1c 7.0–8.9% HbA1c > 9.0% 
6-Months    
    Ischemic stroke events 32 33 7 
    Person-years 1229.7 1173.5 431.8 
    Rate 2.6/100 person-years 2.8/100 person-years 1.6/100 person-years 
    Hazard Ratio (unadjusted) - 1.15 (0.70–1.88) 0.62 (0.27–1.41) 
    Hazard Ratio (adjusted*) - 1.08 (0.65–1.80) 0.56 (0.25–1.29) 
1.5 Years    
    Ischemic stroke events 48 51 16 
    Person-years 1905.7 1684.9 660.0 
    Rate 2.5/100 person-years 3.0/100 person-years 2.4/100 person-years 
    Hazard Ratio (unadjusted) - 1.24 (0.83–1.85) 0.96 (0.55–1.69) 
    Hazard Ratio (adjusted*) - 1.22 (0.80–1.84) 0.94 (0.52–1.69) 
Linear Interpolation    
    Ischemic stroke events 55 59 20 
    Person-years 1953.3 1953.1 712.8 
    Rate 2.8/100 person-years 3.0/100 person-years 2.8/100 person-years 
    Hazard Ratio (unadjusted) - 1.10 (0.77–1.59) 0.94 (0.57–1.57) 
    Hazard Ratio (adjusted*) - 1.11 (0.76–1.63) 0.94 (0.56–1.59) 
 * Adjusted for age, gender, race, congestive heart failure, hypertension, prior thromboembolism, 
coronary artery disease, peripheral arterial disease, proteinuria, significant kidney dysfunction, 
insulin use, and diabetes duration 
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IMPACT OF WARFARIN ON INCIDENCE OF STROKE – A COMPETING 
RISKS ANALYSIS 
 
BACKGROUND 
Atrial fibrillation (AF) is associated with a 5-fold increase in the risk of 
ischemic stroke, and accounts for 15% of all strokes nationally, including more 
than 36% of strokes in those 80 years of age or older.5, 6 Warfarin anticoagulation 
therapy is associated with reduced risk of ischemic stroke in patients with AF.7–9 
Warfarin use is also associated with reduced stroke severity and short-term 
mortality following a stroke.20 
To date, studies examining the association between warfarin therapy and 
incidence of stroke have not taken competing risks into account. A competing 
risk is an event other than the outcome of interest, whose occurrence precludes 
the ability to observe the outcome of interest for reasons such as dying from 
another cause, or experiencing an illness that prevents the diagnosis of the 
outcome of interest.66 Given that the prevalence of AF is strongly associated with 
increasing age, with a prevalence of nearly 10% among those 80 years of age or 
older and a median age of 75 years, deaths from comorbid conditions are 
common.1, 4 Accounting for competing risks may provide greater understanding 
of the real-world impact of AF on stroke risk and the preventative effect of 
anticoagulation over a multiyear time span. 
Time to event statistical approaches such as Kaplan-Meier (KM) survival 
analysis and Cox proportional hazards regression are often used to account for 
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unequal follow-up time among participants. In KM analyses, censored subjects 
are considered to be at risk for the outcome of interest for the duration of the 
study. Most often, competing risk events are ignored in analyses; however, 
ignoring competing risks may overestimate the actual incidence of the outcome 
of interest.66–68 Since patients taking warfarin may be different from patients not 
taking warfarin in terms of comorbid illness, measures of association from 
models which do not account for competing risks may not represent what is 
actually occurring in practice.21 
The primary approaches to competing risk regression include estimation 
of the cause-specific and the subdistribution hazards. The cause-specific hazard 
is estimated by constructing a proportional hazards model separately for each 
event type, where individuals who experience the competing event type are 
treated as censored observations. In this situation, the risk set is modified over 
time by removing individuals from remaining risk sets as they have either event, 
so the competing event influences the measure of association for the event of 
interest by removing at risk person-time from the risk set over time.69 In this 
situation, whether the event of interest is observed is dependent on both the 
cause –specific hazard ratio for the event of interest and the cause-specific 
hazard ratio for the competing event.69  
Fine and Gray developed a regression modeling approach for competing 
risks analysis which is a modification of the Cox proportional hazards model and 
measures the subdistribution cumulative incidence function.68 This method 
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considers the effect of predictors on the subdistribution hazard function 
accounting for the presence of competing risks.68 In contrast to the cause-
specific hazard where individuals who have a competing event are censored, in 
the subdistribution hazard model these individuals remain in the risk set and 
serve as a proxy for those who will never experience the event of interest.69, 71 
The subdistribution hazard is then defined as the probability of the event of 
interest given that an individual has survived up to that time without having the 
event of interest or has had the competing event prior to that time.69  
This study aimed to assess the importance of accounting for competing 
risk events in a population of AF patients, where competing events occurred 
frequently. 
 
METHODS 
Source population 
 This study utilized the ATRIA cohort described in study 1 and study 2, 
which includes 13,559 patients with AF with follow-up from 1996–2003. For this 
study, all patients were followed prospectively from their index date (date of the 
first diagnosis of AF during the period of cohort assembly) until the event of 
interest, a competing risk event, or withdrawal from the health plan. 
Definitions of variables 
 Longitudinal warfarin exposure was assessed using an algorithm validated 
by chart review based on the number of days supplied per warfarin prescription 
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and intervening INR measurements.19 Using this algorithm, continuous warfarin 
exposure was assumed for periods where the second of any 2 consecutive filled 
prescriptions begins within 60 days of the last day supplied by the previous 
prescription. For periods between consecutive warfarin prescriptions longer than 
60 days, continuous warfarin therapy was assumed if there were intervening INR 
measurements at least every 42 days.  If INR measurements were less 
frequently obtained, the patient was considered to not be taking warfarin from 
day 31 after the end date of the first prescription until the start date of the next 
prescription.  The 30-day time period between warfarin exposure periods was 
used to accommodate reductions in warfarin doses as well as skipped warfarin 
doses. Patients without warfarin prescriptions were considered not to be taking 
warfarin. 
 The outcome of interest was thromboembolism. Cases of 
thromboembolism (TE) included both ischemic stroke and systemic embolism. 
Ischemic stroke was identified as described in Study 2. A valid peripheral 
embolism is defined as an embolus identified by radiographic imaging, 
intraoperative examination, or pathological findings in the absence of underlying 
atherosclerotic disease in the affected artery.  If a patient had multiple TE events 
during the study follow-up period, only the first TE event was considered a valid 
event. For this analysis, all deaths from any cause were considered competing 
risk events. Deaths were determined through reviewing medical charts, health 
plan databases, Social Security Administration vital status file, and the 
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comprehensive California State death certificate registry. 
Patient characteristics, including data on patient age (<65 years, 65–74 
years, 75–84 years, ≥85 years), gender, and self-reported race/ethnicity (white, 
black/African American, Asian/Pacific Islander, Hispanic ethnicity, 
other/unknown) were obtained from administrative databases. History of 
comorbid conditions, including prior ischemic stroke, chronic heart failure, 
coronary disease, peripheral artery disease, hypertension, and diabetes mellitus 
were collected from clinical inpatient and ambulatory databases using validated 
algorithms and were assessed using data during the five years prior to the 
patient’s index date and were updated during the follow-up period. Kidney 
dysfunction (defined as estimated glomerular filtration rate [eGFR] < 45 
ml/min/1.73 m2) was calculated from laboratory values using the Chronic Kidney 
Disease Epidemiology (CKD-EPI) Collaboration formula.33 Patients without an 
eGFR value in the prior year were considered to have normal renal function and 
patients on dialysis were considered to have kidney dysfunction.  Proteinuria was 
defined as a urine dipstick protein result of ≥1+ (30 mg/dL or higher) in the 
absence of potential urinary tract infection found in laboratory databases.56 
Patients without a urine dipstick protein laboratory result in the prior year were 
considered to not have proteinuria. All health-related variables were 
dichotomized. For all patients, the CHADS2,26 CHA2DS2-VASc,34 and ATRIA35 
stroke risk scores were calculated. 
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Statistical analysis 
 We assessed distributions of each covariate by exposure status (warfarin 
use) and by the occurrence of outcome events (TE events). Additionally, we 
calculated the rate of TE events and death by warfarin status. We used extended 
Cox proportional hazards regression to estimate unadjusted and adjusted cause-
specific incidence rate ratios for both the outcome of interest (TE events) and the 
competing risk event (death) while accounting for different lengths of follow-up 
among patients and time-varying exposure status while adjusting for time-varying 
covariables. We then used the Competing Risk Regression (CRR) approach, 
developed by Fine and Gray, which is based on the Cox Proportional Hazards 
model and accounts for competing risk events and compared this result to our 
results for the outcome of interest from the cause-specific hazard models.68 
Cases occurred at the time of TE event and patients were censored at the time of 
disenrollment from the Kaiser Permanente network, or at the end of the follow-up 
period, September 30, 2003. All deaths were considered competing risk events. 
As a secondary analysis, we limited follow-up to 1-year after the index date in 
order to have fewer competing risk events and compared results to our primary 
analysis, which used the full ATRIA follow-up period (1996–2003). Additionally, 
we performed analyses stratified by age (<75 years and ≥ 75 years).   
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RESULTS 
Characteristics of the study population 
 Patients who were using warfarin at baseline were compared to patients 
who were not using warfarin at baseline (Table 3.1). Patients using warfarin were 
less likely to be in the oldest age group, less likely to be female, more likely to 
have had a prior stroke, and more likely to have diagnoses of diabetes, coronary 
disease, hypertension, and chronic heart failure, and less likely to have 
significant kidney dysfunction. Additionally, patients using warfarin had higher 
CHADS2, CHA2DS2-VASc, and ATRIA stroke risk scores. 
Association between warfarin and mortality 
 Over the full ATRIA follow-up period, there were 4412 deaths (2637 
deaths off warfarin, 1777 deaths on warfarin), which are competing death events 
for our association of interest (warfarin and thromboembolism). The rate of death 
was much higher in the non-warfarin group (8.1 deaths/100 person-years) 
compared to the warfarin group (5.5 deaths/100 person-years) (Table 3.2). The 
adjusted cause-specific hazard ratio for the outcome of death comparing warfarin 
use to non-use of warfarin was 0.69 (95% CI: 0.64–0.73).   
Association between warfarin and thromboembolism 
 Over the full ATRIA follow-up period, there were 1092 TE events (1017 
ischemic strokes and 75 systemic emboli), with a higher rate in the non-warfarin 
group (687 events for a rate of 2.1/100 person-years) compared to the warfarin 
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group (405 events for a rate of 1.3/100 person-years). The cause-specific hazard 
ratio indicates a large reduction in rate of thromboembolism with warfarin use 
compared to not using warfarin in unadjusted (HR: 0.61, 95% CI: 0.54–0.69) and 
adjusted (HR: 0.57, 95% CI: 0.50–0.65) analyses (Table 3.3).  
 In the subdistribution hazard models which account for competing death 
events, warfarin was still associated with a reduced rate of thromboembolism in 
unadjusted (HR: 0.84, 95% CI: 0.74–0.95) and adjusted (HR: 0.87, 95% CI: 
0.77–0.99) models, however, this association was substantially attenuated 
compared to the association observed in the cause-specific models (Table 3.3). 
Association between warfarin and mortality – 1-year of follow-up 
 Table 3.4 presents the same associations as Table 3.2, but limits follow-
up to 1-year after the index date for each patient. During this follow-up period, 
there were 648 competing death events. The rate of death was lower than during 
the full ATRIA follow-up period, but was still higher in the non-warfarin group 
(5.6/100 person-years) than in the warfarin group (4.3/100 person-years). The 
adjusted cause-specific hazard ratio for the outcome of death comparing warfarin 
use to non-use of warfarin during this 1-year follow-up period was 0.75 (95% CI: 
0.64–0.88). 
Association between warfarin and thromboembolism – 1-year of follow-up 
 During the 1-year period following each patient’s index date, there were 
294 TE events (Table 3.5). The rate of TE in this 1-year period was higher than 
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during the full ATRIA follow-up period, and remains higher in the non-warfarin 
group (2.8/100 person-years) than in the warfarin group (1.7/100 person-years). 
Similar to the full ATRIA follow-up period, the cause-specific hazard ratio during 
1-year of follow-up indicates a reduced risk of thromboembolism for those taking 
warfarin compared to those not using warfarin in unadjusted (HR: 0.62, 95% CI: 
0.49–0.79) and adjusted (HR: 0.55, 95% CI: 0.43–0.71) analyses.  
With many fewer competing death events and more similar death rates for 
warfarin and non-warfarin groups occurring during the first year of follow-up, the 
subdistribution hazard ratio during this time-period was similar to the cause-
specific hazard ratio. The unadjusted subdistribution hazard ratio was 0.64 (95% 
CI: 0.51–0.82) and the adjusted subdistribution hazard ratio was 0.59 (95% CI: 
0.46–0.75) (Table 3.5). 
Age-stratified results 
 In analyses using the full follow-up period stratified by age (<75 years and 
≥ 75 years), there were 1005 competing death events in the younger age group 
and 3407 competing death events in the older age group. The rate of mortality 
was much lower in the younger age group compared to the older age group. 
Patients ≥ 75 years who were not using warfarin had a much higher rate of 
mortality (13.0/100 person-years) compared to patients ≥ 75 years who were 
using warfarin (7.4/100 person-years) (Table 3.6). In patients < 75 years, the rate 
of mortality was similar in non-warfarin and warfarin users. 
 The rate of TE events was much lower in the younger age group (295 TE 
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events, 0.94/100 person-years) than in the older age group (797 TE events, 
2.37/100 person-years). In patients < 75 years, there was a small reduction in 
rate of TE events in the warfarin group compared to the non-warfarin group in 
unadjusted analyses (Cause-specific HR: 0.87, 95% CI: 0.69–1.10), while this 
protective association was larger in adjusted analyses (Cause-specific HR: 0.63, 
95% CI: 0.50–0.80) (Table 3.7). In patients ≥ 75 years, there was a more 
pronounced inverse association observed for warfarin compared to non-warfarin 
in both unadjusted (Cause-specific HR: 0.51, 95% CI: 0.44–0.59) and adjusted 
(Cause-specific HR: 0.52, 0.45–0.60) analyses. In both the younger (adjusted 
subdistribution HR: 0.90, 95% CI: 0.71–1.14) and older (adjusted subdistribution 
HR: 0.78, 95% CI: 0.67–0.91) age groups, the inverse association between 
warfarin and TE events was closer to the null after accounting for competing 
death events. 
 
DISCUSSION 
 Within a large ambulatory cohort of patients with nonvalvular atrial 
fibrillation in clinical practice, warfarin was associated with a reduced rate of 
thromboembolism in cause-specific hazard models that did not account for 
competing risk events. This protective association between warfarin and 
thromboembolism was attenuated when using a modeling approach that 
accounted for the large number of competing death events that occurred in this 
population. In analyses stratified by age, hazard ratios were closer to the null 
after accounting for competing death events in both age groups, but the 
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protective association between warfarin and thromboembolism remained in both 
younger and older patients. When analyses were limited to 1-year of follow-up 
with many fewer competing death events, results were similar in models that did 
and did not account for competing death events. 
 Prior research has been conducted in the ATRIA cohort to determine if the 
dramatic reduction in risk of stroke with use of warfarin as demonstrated in 
clinical trials would translate to typical clinical practice.9 The patients who 
participated in clinical trials were highly selected, with fewer elderly patients and 
with fewer comorbid conditions than may be observed in clinical practice.7, 72 A 
prior ATRIA study conducted using the first 3-years of follow-up in the cohort 
demonstrated that warfarin reduced the risk of thromboembolism by 51% 
compared with no warfarin therapy, showing that findings from randomized trials 
translated well into clinical practice.9 In the current study, we demonstrate that 
the reduction in risk of stroke with use of warfarin in clinical practice is not as 
dramatic as previously reported if competing death events are accounted for. 
With the older age of our ambulatory cohort (45% ≥ 75 years), competing events 
occurred frequently (4414 deaths). Accounting for competing death events in a 
cohort of AF patients by using the subdistribution hazard approach may give a 
more realistic estimate of the benefit of warfarin therapy in preventing stroke in 
clinical care given the high rate of mortality in this population. When limiting our 
follow-up to 1-year (a period of time comparable to clinical trials), there were far 
fewer competing death events, the death rates in the warfarin and non-warfarin 
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groups were more similar, and the results that did and did not account for 
competing risks were comparable.  
 For patients with AF, the use of anticoagulants is driven by the absolute 
benefit (thromboembolic events prevented) minus the absolute harm 
(hemorrhagic events induced).24 Our results indicate that warfarin is associated 
with a reduced rate of thromboembolism as previously established7–9, but 
patients with AF may not be surviving long enough to realize this protective 
association, so the absolute benefit of warfarin in clinical care may be 
overestimated in calculations of net clinical benefit. Prior work has also shown 
that net clinical benefit is greatest in the oldest individuals.24 Older AF patients (≥ 
75 years) in our cohort experienced high rates of mortality (particularly in the 
non-warfarin group), so the hazard ratio demonstrating the protective effect of 
warfarin accounting for competing death events is substantially attenuated from 
models ignoring competing events. Despite this attenuation, however, older 
patients using warfarin still experienced considerable stroke reduction benefits. In 
younger individuals (< 75 years), the protective association observed for warfarin 
was also attenuated despite the rate of mortality being slightly higher in the 
warfarin group. However, simulation studies have shown that substantial 
correlation between competing events may have this effect on the subdistribution 
hazard (i.e. patients likely to experience a TE event may also be at higher risk of 
death).73 
 This study was strengthened by utilizing a large cohort of AF patients, with 
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long-term comprehensive follow-up, and a large number of outcome events. All 
thromboembolism events were adjudicated by physicians or nurses using a 
standardized medical record review protocol which minimizes errors in case 
ascertainment. Competing death events were ascertained from comprehensive 
databases and are expected to be complete for all patients. In addition, we were 
able to assess longitudinal warfarin exposure using a validated algorithm which 
utilizes both comprehensive pharmacy and laboratory databases.  
 This study also has several potential limitations. There may still be 
residual confounding by indication, despite controlling for important stroke risk 
factors in multivariable models, which may underestimate the efficacy of warfarin. 
However, we include measurements of all stroke risk factors from CHADS2, 
CHA2DS2-VASc, and ATRIA stroke risk scores, so residual confounding by 
indication should be small. We did not have information on aspirin use for 
patients not prescribed warfarin, so our non-warfarin group includes a mix of 
patients using aspirin and patients not taking aspirin or warfarin. Additionally, our 
search strategy may have missed a small number of thromboembolic events that 
did not lead to hospitalization, however, we do not expect these missed events to 
differ by warfarin status. 
 In conclusion, this study demonstrates the effect of accounting for 
competing death events when evaluating anticoagulants in patients with AF in 
clinical care. Since patients who are prescribed anticoagulants are very different 
from patients not prescribed anticoagulants with regards to mortality risk, 
  
63
analyses that account for competing death events may differ considerably from 
cause-specific hazard estimates. By accounting for competing death events, the 
results presented in this study may reflect a more realistic estimate of the stroke 
reducing benefits of warfarin for patients with AF not currently anticoagulated in 
clinical care. 
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Table 3.1: Patient characteristics by warfarin status at baseline 
 
 No Warfarin 
 (n=6353) 
Warfarin 
(n=7206) 
P-Value 
Patient Characteristics    
Age category   <0.001 
    <65 years 1491 (23.5%) 1542 (21.4%)  
    65–74 years 1770 (26.1%) 2614 (36.3%)  
    75–84 years 2165 (34.1%) 2602 (36.1%)  
    ≥85 years 927 (14.6%) 448 (6.2%)  
Gender, female 2857 (45.0%) 2938 (40.8%) <0.001 
Race    0.01 
    White 5430 (85.5%) 6251 (86.8%)  
    Black/African American 255 (4.0%) 275 (3.8%)  
    Asian/Pacific Islander 348 (5.5%) 381 (5.3%)  
    Hispanic 161 (2.5%) 179 (2.5%)  
    Other/Unknown 159 (2.5%) 120 (1.7%)  
Comorbid conditions    
Prior stroke 366 (5.8%) 886 (12.3%) <0.001 
Diabetes mellitus 930 (14.6%) 1305 (18.1%) <0.001 
Coronary artery disease 1716 (27.0%) 2210 (30.7%) <0.001 
Peripheral artery disease 131 (2.1%) 190 (2.6%) 0.03 
Hypertension 3147 (49.5%) 3760 (52.2%) 0.002 
Chronic heart failure 1658 (26.1%) 2494 (34.6%) <0.001 
Significant kidney dysfunction 926 (14.6%) 949 (13.2%) 0.02 
Proteinuria 782 (12.3%) 901 (12.5%) 0.73 
Predicted Stroke Risk    
CHADS2, mean (SD) 1.64 (1.18) 2.02 (1.28) <0.001 
CHA2DS2-VASc, mean (SD) 3.22 (1.53) 3.68 (1.60) <0.001 
ATRIA stroke risk score, mean (SD) 5.89 (2.53) 6.65 (2.40) <0.001 
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Table 3.2: Association between time-varying warfarin and mortality over the full 
ATRIA follow-up period 
 
 No Warfarin Warfarin 
Death events 2637 1777 
Person-years 32,601.9 32,123.6 
Rate 8.1/100 person-years 5.5/100 person-years 
Cause-Specific Hazard Ratio (Death) – 
unadjusted 
- 0.68 (0.64–0.72) 
Cause-Specific Hazard Ratio (Death) – 
adjusted* 
- 0.69 (0.64–0.73) 
* Adjusted for age, gender, race, prior stroke, diabetes, coronary disease, peripheral 
artery disease, hypertension, significant kidney dysfunction, proteinuria 
 
Table 3.3: Association between time-varying warfarin use and thromboembolism 
over the full ATRIA follow-up period (cause-specific and subdistribution hazards) 
 
 No Warfarin Warfarin 
Thromboembolism events 687 405 
Person-years 32,601.9 32,123.6 
Rate 2.1/100 person-years 1.3/100 person-years 
Cause-Specific Hazard Ratio (TE) – 
unadjusted 
- 0.61 (0.54–0.69) 
Cause-Specific Hazard Ratio (TE) – 
adjusted* 
- 0.57 (0.50–0.65) 
Subdistribution Hazard Ratio – unadjusted - 0.84 (0.74–0.95) 
Subdistribution Hazard Ratio – adjusted* - 0.87 (0.77–0.99) 
* Adjusted for age, gender, race, prior stroke, diabetes, coronary disease, peripheral 
artery disease, hypertension, significant kidney dysfunction, proteinuria 
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Table 3.4: Association between time-varying warfarin use and mortality over 1-
year of follow-up 
 
 No Warfarin Warfarin 
Death events 385 263 
Person-years  6918.2 6120.4 
Rate 5.6/100 person-years 4.3/100 person-years 
Cause-Specific Hazard Ratio (Death) – 
unadjusted 
- 0.77 (0.66–0.91) 
Cause-Specific Hazard Ratio (Death) – 
adjusted* 
- 0.75 (0.64–0.88) 
* Adjusted for age, gender, race, prior stroke, diabetes, coronary disease, peripheral 
artery disease, hypertension, significant kidney dysfunction, proteinuria 
 
 
Table 3.5: Association between time-varying warfarin use and thromboembolism 
over1-year of follow-up (cause-specific and subdistribution hazards) 
 
 No Warfarin Warfarin 
Thromboembolism events 191 103 
Person-years (py) 6918.2 6120.4 
Rate 2.8/100py 1.7/100py 
Cause-Specific Hazard Ratio (TE) – unadjusted - 0.62 (0.49–0.79) 
Cause-Specific Hazard Ratio (TE) – adjusted* - 0.55 (0.43–0.71) 
Subdistribution Hazard Ratio – unadjusted - 0.64 (0.51–0.82) 
Subdistribution Hazard Ratio – adjusted* - 0.59 (0.46–0.75) 
* Adjusted for age, gender, race, prior stroke, diabetes, coronary disease, peripheral 
artery disease, hypertension, significant kidney dysfunction, proteinuria 
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Table 3.6: Association between time-varying warfarin use and mortality over the 
full ATRIA follow-up period stratified by age (< 75 years and ≥ 75 years) 
 
 Age < 75 years Age ≥ 75 years 
 No Warfarin Warfarin No Warfarin Warfarin 
Death events 492 513 2141 1266 
Person-years 16,172.8 15,136.6 16,474.4 17,123.5 
Rate 3.0/100   
person-years 
3.4/100    
person-years 
13.0/100 
person-years 
7.4/100    
person-years 
Cause-Specific Hazard 
Ratio (Death) – unadjusted 
- 1.13 (0.99–1.28) - 0.56 (0.52–0.60) 
Cause-Specific Hazard 
Ratio (Death) – adjusted* 
- 0.78 (0.69–0.89) - 0.56 (0.52–0.60) 
* Adjusted for age, gender, race, prior stroke, diabetes, coronary disease, peripheral 
artery disease, hypertension, significant kidney dysfunction, proteinuria 
 
Table 3.7: Association between time-varying warfarin use and thromboembolism 
over the full ATRIA follow-up period (cause-specific and subdistribution hazards) 
stratified by age (< 75 years and ≥ 75 years) 
 
 Age < 75 years Age ≥ 75 years 
 No Warfarin Warfarin No Warfarin Warfarin 
Thromboembolism events 163 132 522 275 
Person-years 16,172.8 15,136.6 16,474.4 17,123.5 
Rate 1.0/100 
person-years 
0.9/100    
person-years 
3.2/100     
person-years 
1.6/100    
person-years 
Cause-Specific Hazard 
Ratio (TE) – unadjusted 
- 0.87 (0.69–1.10) - 0.51 (0.44–0.59) 
Cause-Specific Hazard 
Ratio (TE) – adjusted* 
- 0.63 (0.50–0.80) - 0.52 (0.45–0.60) 
Subdistribution Hazard 
Ratio – unadjusted 
- 1.01 (0.80–1.27) - 0.75 (0.65–0.87) 
Subdistribution Hazard 
Ratio – adjusted* 
- 0.90 (0.71–1.14) - 0.78 (0.67–0.91) 
* Adjusted for age, gender, race, prior stroke, diabetes, coronary disease, peripheral 
artery disease, hypertension, significant kidney dysfunction, proteinuria 
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CONCLUSIONS 
 The studies in this dissertation examined the risk of stroke and mortality in 
patients with atrial fibrillation (AF) and the results of these studies may assist 
physicians and patients in the decision to use anticoagulation therapy. The first 
study examined whether short and long-term mortality following a major 
gastrointestinal (GI) hemorrhage were impacted by whether the patient was 
using warfarin at the time of the hemorrhagic event. This study evaluated these 
associations in two prospective cohorts from Kaiser Permanente Northern and 
Southern California, the Anticoagulation and Risk Factors in Atrial fibrillation 
(ATRIA) cohort and the more modern ATRIA-CVRN (Cardiovascular Research 
Network) cohort. Utilizing propensity score adjustment, there was no association 
between warfarin use and 30-day mortality in the ATRIA cohort (adjusted 
mortality rate ratio [mRR]: 0.97, 95% CI: 0.54–1.74) (Table 1.2). In contrast, in 
ATRIA-CVRN warfarin use at the time of GI hemorrhage was associated with a 
substantially lower short-term mortality rate (adjusted mRR: 0.38, 95% CI: 0.17–
0.83) (Table 1.2). This difference was mainly due to a much lower proportion of 
ATRIA-CVRN patients dying within 30-days who were using warfarin compared 
to the ATRIA cohort (4.8% vs. 11.2%), while the proportion of patients who died 
within 30-days was similar between the two cohorts for patients not using 
warfarin (13.9% in ATRIA-CVRN vs. 13.1% in ATRIA). In stratified analyses, 
warfarin use appeared more strongly associated with lower 30-day mortality 
among the oldest group of patients (≥ 85 years) in both cohorts, despite wide 
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confidence intervals. Results for the association between warfarin usage and 1-
year mortality indicate a reduced rate of mortality in both cohorts, though this 
reduction is heavily influenced by the first 30-days in the ATRIA-CVRN cohort 
(Table 1.3). The results for 30-day mortality for GI hemorrhage are markedly 
different from those for intracranial hemorrhage, where use of warfarin drastically 
increases short-term mortality. 
 The second study was designed to determine which characteristics of 
diabetes among diabetics with AF are most important in predicting ischemic 
stroke. We specifically examined time-varying measures of duration of diabetes 
(<3 years and ≥ 3 years) and glycemic control (HbA1c <7.0%, 7.0–8.9%, and ≥ 
9.0%). Estimated diabetes duration of 3 or more years was associated with a 
much higher rate of ischemic stroke compared to both diabetic patients with 
duration < 3 years (adjusted hazard ratio [HR]: 1.75, 95% CI: 1.05–2.90) and 
non-diabetic patients (adjusted HR: 1.62, 95% CI: 1.31–2.01) (Table 2.4). This 
increase in rate of ischemic stroke appeared to be independent of age as we 
observed an increase in patients <75 years (adjusted HR: 1.51, 95% CI: 0.80–
2.85) and patients ≥ 75 years (adjusted HR: 2.14, 95% CI: 1.05–4.35), though 
the association was greater in the older age group (Table 2.5). Increased HbA1c 
values did not appear to be associated with an increased rate of ischemic stroke 
(HbA1c ≥ 9.0%, adjusted HR: 1.04, 95% CI: 0.57–1.91; HbA1c 7.0–8.9%, 
adjusted HR: 1.17, 95% CI: 0.75–1.82) compared to patients with well-controlled 
HbA1c values (<7.0%) (Table 2.6). Since many patients did not have HbA1c 
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measurements at regular intervals, missing data for this analysis was a concern. 
In our primary analysis, we allowed a HbA1c value to be used for up to a 1-year 
period if there were not more frequent measurements. As a sensitivity analysis, 
we also performed analyses where HbA1c values were valid for only 6-months, 
up to 1.5 years, and where values were assessed using linear interpolation and 
results were similar to our primary analysis (Table 2.7). Given the relatively small 
association between the diagnosis of diabetes and ischemic stroke in several 
published studies, accounting for duration of diabetes may improve stroke risk 
models for patients with AF.  
 The third study of this dissertation aimed to determine the importance of 
accounting for competing death events when evaluating the association between 
warfarin use and thromboembolism in patients with AF. Prior studies conducted 
in clinical care have shown that warfarin markedly reduces the rate of 
thromboembolism, but these studies have not accounted for competing death 
events. In this study, we found that patients not taking warfarin had a much 
higher rate of mortality during follow-up compared to patients taking warfarin. In 
cause-specific hazard models, we confirmed results from prior studies by 
showing a large reduction in thromboembolism in patients taking warfarin 
(adjusted HR: 0.57, 95% CI: 0.50–0.65) in models that ignore competing risks 
(Table 3.3). In the subdistribution hazard model that accounted for competing 
death events, warfarin was still associated with a reduced rate of 
thromboembolism, but the hazard ratio was attenuated compared to models that 
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ignored competing death events (adjusted HR: 0.87, 95% CI: 0.77–0.99) (Table 
3.3). When restricting these analyses to only 1-year of follow-up the cause-
specific hazard ratio and the subdistribution hazard ratio which accounted for 
competing death events were similar, as there were many fewer competing 
events when limiting follow-up (Table 3.5). In analyses stratified by age (< 75 
years and ≥ 75 years), the hazard ratio was attenuated in both age groups (Table 
3.7). Despite the subdistribution hazard ratio being closer to the null in the older 
age group, a large benefit remained (adjusted HR: 0.78, 95% CI: 0.67–0.91) 
since the cause-specific hazard ratio was so low in this group (adjusted HR: 0.52, 
95% CI: 0.45–0.60) (Table 3.7). Warfarin is associated with a reduced rate of 
thromboembolism, however, given the older age of the AF population and the 
high rate of mortality, many of these individuals may not be surviving long 
enough to realize this benefit. 
 In summary, the studies comprising this dissertation suggest several 
important conclusions. GI hemorrhages on warfarin are certainly no worse, and 
may be less life-threatening than those occurring off warfarin. Duration of 
diabetes is a more important predictor of ischemic stroke and glycemic control, 
and including an estimate of duration may improve stroke risk models which 
currently only include a diagnosis of diabetes as a predictor. Lastly, failing to 
account for competing death events in analyses examining the association 
between warfarin and thromboembolism may overestimate the effect of warfarin 
in clinical care.
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APPENDICES 
Appendix 1: ICD-9 codes used to identify potential gastrointestinal 
hemorrhages 
 
ATRIA ATRIA-CVRN Description 
455.2 455.2 Internal hemorrhoids with other complication      
455.5 455.5 External hemorrhoids with other complication     
455.8 455.8 Unspecified hemorrhoids with other complication      
456.0 456.0 Esophageal varices with bleeding 
456.2 456.2 Esophageal varices in diseases classified elsewhere 
459.0 Hemorrhage, unspecified 
501.5 Upper GI bleed secondary to hypercoagulopathy 
501.51 Upper GI bleed secondary to ulcerative esophagitis 
503.93 Gastric varices bleeding 
530.21 Ulcer of esophagus with bleeding     
530.7 530.7 Gastroesophageal laceration-hemorrhage syndrome    
530.82 530.82 Esophageal hemorrhage     
531.0 531.0 Acute gastric ulcer with hemorrhage            
531.01 531.01 Acute gastric ulcer with hemorrhage, with obstruction       
531.2 531.2 Acute gastric ulcer with hemorrhage and perforation    
531.21 531.21 
Acute gastric ulcer with hemorrhage and performation, with 
obstruction     
531.4 531.4 Chronic or unspecified gastric ulcer with hemorrhage    
531.41 531.41 
Chronic or unspecified gastric ulcer with hemorrhage, with 
obstruction   
531.6 531.6 
Chronic or unspecified gastric ulcer with hemorrhage and 
performation          
531.61 531.61 
Chronic or unspecified gastric ulcer with hemorrhage and 
performation, with obstruction   
532.0 532.0 Acute duodenal ulcer with hemorrhage         
532.01 532.01 Acute duodenal ulcer with hemorrhage, with obstruction    
532.2 532.2 Acute duodenal ulcer with hemorrhage and performation   
532.21 532.21 
Acute duodenal ulcer with hemorrhage and performation, with 
obstruction   
532.4 532.4 Chronic or unspecified duodenal ulcer with hemorrhage        
532.41 532.41 
Chronic or unspecified duodenal ulcer with hemorrhage, with 
obstruction        
532.6 532.6 
Chronic or unspecified duodenal ulcer with hemorrhage and 
performation     
532.61 532.61 
Chronic or unspecified duodenal ulcer with hemorrhage and 
performation, with obstruction       
533.0 533.0 Acute peptic ulcer of unspecified site with hemorrhage      
533.01 533.01 
Acute peptic ulcer of unspecified site with hemorrhage, with 
obstruction     
533.2 533.2 
Acute peptic ulcer of unspecified site with hemorrhage and 
perforation    
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533.21 533.21 Acute peptic ulcer of unspecified site with hemorrhage and 
perforation, with obstruction  
533.4 533.4 
Chronic or unspecified peptic ulcer of unspecified site with 
hemorrhage      
533.41 533.41 
Chronic or unspecified peptic ulcer of unspecified site with 
hemorrhage, with obstruction     
533.6 533.6 
Chronic or unspecified peptic ulcer of unspecified site with 
hemorrhage and perforation     
533.61 533.61 
Chronic or unspecified peptic ulcer of unspecified site with 
hemorrhage and perforation, with obstruction      
534.0 534.0 Acute gastrojejunal ulcer with hemorrhage      
534.01 534.01 Acute gastrojejunal ulcer with hemorrhage, with obstruction   
534.2 534.2 Acute gastrojejunal ulcer with hemorrhage and perforation 
534.21 534.21 
Acute gastrojejunal ulcer with hemorrhage and perforation, with 
obstruction      
534.4 534.4 Chronic or unspecified gastrojejunal ulcer with hemorrhage      
534.41 534.41 
Chronic or unspecified gastrojejunal ulcer with hemorrhage, 
with obstruction      
534.6 534.6 
Chronic or unspecified gastrojejunal ulcer with hemorrhage and 
perforation      
534.61 534.61 
Chronic or unspecified gastrojejunal ulcer with hemorrhage and 
perforation, with obstruction    
535.01 535.01 Acute gastritis, with hemorrhage 
535.11 535.11 Atrophic gastritis, with hemorrhage 
535.21 535.21 Gastric mucosal hypertrophy, with hemorrhage 
535.31 535.31 Alcoholic gastritis, with hemorrhage 
535.41 535.41 Other specified gastritis, with hemorrhage 
535.51 535.51 Unspecified gastritis and gastroduodenitis, with hemorrhage 
535.61 535.61 Duodenitis, with hemorrhage 
535.71 Eosinophilic gastritis, with hemorrhage 
537.83 537.83 Angiodysplasia of stomach and duodenum with hemorrhage 
537.84 Dieulafoy lesion (hemorrhagic) of stomach and duodenum 
537.89 Other specified disorders of stomach and duodenum 
562.02 562.02 Diverticulosis of small intestine with hemorrhage 
562.03 562.03 Diverticulitis of small intestine with hemorrhage 
562.12 562.12 Diverticulosis of colon with hemorrhage 
562.13 562.13 Diverticulitis of colon with hemorrhage 
568.81 568.81 Hemoperitoneum (nontraumatic) 
569.3 569.3 Hemorrhage of rectum and anus 
569.85 569.85 Angiodysplasia of intestine with hemorrhage 
578 578 Gastrointestinal hemorrhage 
578.1 578.1 Blood in stool                       
578.9 578.9 Hemorrhage of gastrointestinal tract, unspecified 
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Appendix 2: Baseline patient characteristics among patients with major GI 
hemorrhage from the ATRIA and ATRIA-CVRN cohorts 
 
 ATRIA ATRIA-CVRN P-VALUE 
Patient Characteristics    
Age, mean (SD) 78.5 (8.3) 76.8 (8.5) 0.004 
Race/ethnicity   0.001 
     Asian/Pacific Islander 25 (6.0%) 34 (9.4%)  
     Black 27 (6.5%) 37 (10.3%)  
     Hispanic ethnicity 29 (7.0%) 48 (13.3%)  
     Other/Unknown 4 (1.0%) 3 (0.8%)  
     White 329 (79.5%) 239 (66.2%)  
Gender, women 183 (44.2%) 158 (43.8%) 0.90 
Low educational attainment 20 (4.8%) 101 (28.0%) <0.001 
Low annual household income 37 (8.9%) 54 (15.0%) 0.01 
Current Smoker, Yes   <0.001 
     Yes 17 (4.1%) 21 (5.8%)  
     No 337 (81.4%) 319 (88.4%)  
     Unknown 60 (14.5%) 21 (5.8%)  
Comorbidities and 
Contraindications 
   
History of mechanical falls 46 (11.1%) 58 (16.1%) 0.04 
Prior GI hemorrhage 71 (17.2%) 62 (17.2%) 0.99 
Prior ischemic stroke 58 (14.0%) 32 (8.9%) 0.03 
Diabetes mellitus 128 (30.9%) 155 (42.9%) <0.001 
Coronary disease 184 (44.4%) 148 (41.0%) 0.33 
Hypertension 284 (68.6%) 335 (92.8%) <0.001 
Chronic heart failure 231 (55.8%) 177 (49.0%) 0.06 
Dementia 42 (10.1%) 18 (5.0%) 0.01 
Chronic liver disease 17 (4.1%) 15 (4.2%) 0.97 
Significant kidney dysfunction 88 (21.3%) 47 (13.0%) 0.003 
Systemic cancer 92 (22.2%) 83 (23.0%) 0.80 
Anemia 199 (48.1%) 215 (59.6%) 0.001 
Lung disease    
Transient ischemic attack 139 (33.6%) 177 (49.0%) <0.001 
Medications at Admission 3 (0.7%) 41 (11.4%) <0.001 
Aspirin 39 (9.4%) 210 (58.2%) <0.001 
Other antiplatelet therapies 166 (40.1%) 142 (39.3%) 0.83 
Lipid-lowering agents 18 (4.4%) 39 (10.8%) 0.001 
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Appendix 3a: Baseline Patient Characteristics by Propensity Score Quintile among Patients with GI Hemorrhage from the ATRIA 
Study for 30-day Mortality (Highlighted variables were included in propensity score model) 
 Quintile1 Quintile2 Quintile3 Quintile4 Quintile5 
 W+ W- P W+ W- P W+ W- P W+ W- P W+ W- P 
Variable                
Age (years), mean (SD) 84.5 86.0 0.34 81.0 80.8 0.87 76.8 78.7 0.19 76.1 76.7 0.71 74.3 68.4 0.007 
Race, white 62.5% 69.0% 0.57 87.9% 84.0% 0.76 81.6% 76.5% 0.57 84.5% 92.0% 0.49 78.0% 79.2% 0.90 
Women 62.5% 51.7% 0.37 51.5% 48.0% 0.75 44.9% 58.8% 0.21 34.5% 24.0% 0.34 39.0% 25.0% 0.23 
Low educational 
attainment 
0.0% 0.0% - 0.0% 0.0% - 2.0% 5.9% 0.56 6.9% 0.0% 0.31 13.6% 20.8% 0.51 
Low annual household 
income 
4.2% 3.5% 0.87 0.0% 10.0% 0.152 14.3% 2.9% 0.13 8.6% 4.0% 0.66 15.3% 25.0% 0.35 
Current Smoker, yes 16.7% 13.8% 0.74 18.2% 14.0% 0.61 22.5% 17.7% 0.59 19.0% 24.0% 0.60 20.3% 25.0% 0.64 
History of mechanical 
falls 
8.3% 15.5% 0.49 9.1% 8.0% 1.0 18.4% 17.7% 0.93 10.3% 4.0% 0.67 6.8% 8.3% 1.0 
Prior GI hemorrhage 25.0% 32.8% 0.49 9.1% 12.0% 1.0 16.3% 14.7% 0.84 15.5% 12.0% 1.0 8.5% 29.2% 0.03 
Prior ischemic stroke 4.2% 3.5% 1.0 0.0% 12.0% 0.08 14.3% 14.7% 1.0 17.2% 24.0% 0.55 28.8% 16.7% 0.25 
Diabetes mellitus 33.3% 25.9% 0.49 36.4% 44.0% 0.49 26.5% 23.5% 0.75 29.3% 32.0% 0.81 30.5% 29.2% 0.90 
Coronary disease 45.8% 41.4% 0.71 33.3% 42.0% 0.43 46.9% 38.2% 0.43 44.8% 40.0% 0.68 50.9% 62.5% 0.33 
Hypertension 79.2% 77.6% 0.88 75.8% 74.0% 0.86 77.6% 61.8% 0.12 43.1% 72.0% 0.02 71.2% 58.3% 0.26 
Chronic heart failure 50.0% 55.2% 0.67 48.5% 38.0% 0.34 57.1% 55.9% 0.91 60.3% 76.0% 0.17 62.7% 58.3% 0.71 
Dementia 20.8% 32.8% 0.28 3.0% 4.0% 1.0 10.2% 8.8% 1.0 6.9% 0.0% 0.31 3.4% 4.2% 1.0 
Chronic liver disease 4.2% 3.5% 1.0 0.0% 2.0% 1.0 4.1% 5.9% 1.0 6.9% 12.0% 0.43 3.4% 0.0% 1.0 
Significant kidney 
dysfunction 
25.0% 17.2% 0.54 33.3% 24.0% 0.35 16.3% 26.5% 0.26 15.5% 32.0% 0.09 22.0% 8.3% 0.21 
Systemic cancer 16.7% 22.4% 0.77 27.3% 20.0% 0.44 20.4% 23.5% 0.73 20.7% 20.0% 0.94 23.7% 29.2% 0.61 
Anemia 54.2% 51.7% 0.84 33.3% 44.0% 0.33 49.0% 58.8% 0.38 41.4% 52.0% 0.37 55.9% 37.5% 0.13 
Medications                
Aspirin 16.7% 58.6% 0.001 6.1% 60.0% <0.001 16.3% 58.8% <0.001 10.3% 52.0% <0.001 18.6% 45.8% 0.01 
Other antiplatelet 
therapies 
0.0% 3.5% 1.0 0.0% 2.0% 1.0 0.0% 0.0% - 0.0% 0.0% - 0.0% 0.0% - 
Lipid lowering agents 0.0% 3.5% 1.0 0.0% 2.0% 1.0 2.0% 2.9% 1.0 3.5% 12.0% 0.16 40.7% 20.8% 0.09 
ARBs 8.3% 6.9% 1.0 3.0 4.0 1.0 4.1% 0.0% 0.51 1.7% 12.0% 0.08 5.1% 0.0% 0.55 
Ace Inhibitors 0.0% 19.0% 0.03 36.4% 36.0% 0.97 34.7% 35.3% 0.96 56.9% 60.0% 0.79 62.7% 45.8% 0.16 
W+: using warfarin at time of GI hemorrhage; W-: not using warfarin at time of GI hemorrhage
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Appendix 3b: Baseline Patient Characteristics by Propensity Score Quintile among Patients with GI Hemorrhage from the 
ATRIA-CVRN Study for 30-day Mortality (Highlighted variables were included in propensity score model) 
 Quintile1 Quintile2 Quintile3 Quintile4 Quintile5 
 W+ W- P W+ W- P W+ W- P W+ W- P W+ W- P 
Variable                
Age (years), mean (SD) 79.4 82.0 0.20 77.2 79.2 0.29 76.8 77.5 0.74 75.5 73.4 0.26 73.3 70.4 0.23 
Race, white 63.0% 64.4% 0.90 54.8% 70.7% 0.16 76.0% 70.0% 0.56 65.9% 64.3% 0.89 63.8% 64.3% 0.97 
Women 63.0% 57.8% 0.66 64.5% 56.1% 0.47 36.0% 39.1% 0.80 40.9% 46.4% 0.64 20.7% 14.3% 0.72 
Low educational attainment 33.3% 24.4% 0.41 25.8% 34.2% 0.45 36.0% 30.4% 0.64 18.2% 35.7% 0.09 24.1% 14.3% 0.72 
Low annual household 
income 
11.1% 11.1% 1.0 12.9% 14.6% 1.0 20.0% 26.1% 0.56 11.4% 10.7% 1.0 19.0% 7.1% 0.44 
Current Smoker, yes 22.2% 8.9% 0.16 16.1% 12.2% 0.74 10.0% 13.0% 0.70 6.8% 14.3% 0.42 6.9% 21.4% 0.13 
History of mechanical falls 33.3% 24.4% 0.41 12.9% 26.8% 0.15 14.0% 4.4% 0.42 2.3% 17.9% 0.02 8.6% 28.6% 0.07 
Prior GI hemorrhage 22.2% 33.3% 0.32 29.0% 14.6% 0.14 18.0% 17.4% 0.95 9.1% 21.4% 0.17 5.2% 0.0% 1.0 
Prior ischemic stroke 14.8% 2.2% 0.06 6.5% 7.3% 1.0 13.0% 6.0% 0.37 9.1% 10.7% 1.0 12.1% 14.3% 1.0 
Diabetes mellitus 33.3% 53.3% 0.10 58.1% 46.3% 0.32 62.0% 26.1% 0.004 34.1% 50.0% 0.18 24.1% 35.7% 0.50 
Coronary disease 25.9% 46.7% 0.08 29.0% 31.7% 0.81 46.0% 39.1% 0.58 34.1% 39.3% 0.65 60.3% 35.7% 0.10 
Hypertension 100.0% 97.8% 1.0 96.8% 95.1% 1.0 94.0% 95.7% 1.0 93.2% 96.4% 1.0 81.0% 78.6% 1.0 
Chronic heart failure 48.2% 53.3% 0.67 41.9% 39.0% 0.80 58.0% 65.2% 0.56 36.4% 53.6% 0.151 53.5% 35.7% 0.23 
Dementia 22.2% 24.4% 0.83 0.0% 0.0% - 0.0% 2.0% 1.0 0.0% 0.0% - 0.0% 0.0% - 
Chronic liver disease 3.7% 6.7% 1.0 6.5% 2.4% 0.57 4.0% 8.7% 0.58 4.6% 7.1% 0.64 0.0% 0.0% - 
Significant kidney 
dysfunction 
14.8% 11.1% 0.72 3.2% 12.2% 0.23 16.0% 26.1% 0.35 13.6% 17.9% 0.74 12.1% 0.0% 0.33 
Systemic cancer 14.8% 17.8% 1.0 25.8% 36.6% 0.33 28.0% 8.7% 0.06 13.6% 21.4% 0.52 27.6% 28.6% 1.0 
Anemia 85.2% 73.3% 0.24 54.8% 75.6% 0.06 66.0% 65.2% 0.95 56.8% 50.0% 0.57 31.0% 42.9% 0.53 
Lung disease 48.2% 42.2% 0.62 38.7% 36.6% 0.85 46.0% 34.8% 0.37 56.8% 57.1% 0.98 46.6% 64.3% 0.23 
Transient ischemic attack 3.7% 4.4% 1.0 9.7% 7.3% 1.0 6.0% 4.4% 1.0 6.8% 3.6% 1.0 8.6% 14.3% 0.62 
Medications                
Aspirin  22.2% 64.4% 0.001 41.9% 58.5% 0.16 32.0% 56.5% 0.05 36.4% 71.4% 0.004 51.7% 71.4% 0.18 
Other antiplatelet therapies 11.1% 15.6% 0.73 12.9% 14.6% 1.0 12.0% 13.0% 1.0 6.8% 10.7% 0.67 10.3% 0.0% 0.58 
Lipid lowering agents 25.9% 33.3% 0.51 51.6% 41.5% 0.39 68.0% 47.8% 0.10 72.7% 85.7% 0.20 75.9% 71.4% 0.74 
ARBs 7.4% 13.3% 0.70 6.5% 9.8% 0.69 18.0% 8.7% 0.48 6.8% 7.1% 1.0 12.1% 14.3% 1.0 
Ace Inhibitors 51.9% 40.0% 0.33 32.3% 39.0% 0.55 36.0% 43.5% 0.54 40.9% 35.7% 0.66 36.2% 50.0% 0.34 
W+: using warfarin at time of GI hemorrhage; W-: not using warfarin at time of GI hemorrhage 
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Appendix Table 3c: Baseline Patient Characteristics by Propensity Score Quintile among Patients with GI Hemorrhage from the 
ATRIA Study for Longer-term Mortality (Highlighted variables were included in propensity score model) 
 Quintile1 Quintile2 Quintile3 Quintile4 Quintile5 
 W+ W- P W+ W- P W+ W- P W+ W- P W+ W- P 
Variable                
Age (years), mean (SD) 84.3 86.1 0.23 80.7 80.3 0.77 76.7 78.5 0.23 73.6 73.4 0.88 73.8 69.7 0.11 
Race, white 78.3% 74.5% 0.73 82.9% 83.3% 0.96 84.6% 84.4% 1.0 83.0% 83.3% 1.0 76.0% 81.0% 0.76 
Women 47.8% 44.7% 0.80 34.3% 41.7% 0.52 46.2% 59.4% 0.27 48.9% 29.2% 0.11 32.0% 28.6% 0.78 
Low educational 
attainment 
0.0% 0.0% - 0.0% 0.0% - 0.0% 0.0% - 0.0% 0.0% - 14.0% 19.1% 0.72 
Low annual household 
income 
8.7% 6.4% 1.0 2.9% 11.1% 0.36 10.3% 3.1% 0.37 6.4% 4.2% 1.0 16.0% 23.8% 0.51 
Current Smoker, yes 8.7% 8.5% 1.0 20.0% 13.9% 0.49 23.1% 18.8% 0.66 17.0% 25.0% 0.53 24.0% 23.8% 0.99 
History of mechanical 
falls 
8.7% 14.9% 0.71 5.7% 8.3% 1.0 30.8% 15.6% 0.14 2.1% 0.0% 1.0 6.0% 4.8% 1.0 
Prior GI hemorrhage 17.4% 38.3% 0.08 20.0% 16.7% 0.72 12.8% 9.4% 0.72 12.8% 8.3% 0.71 12.0% 23.8% 0.28 
Prior ischemic stroke 30.4% 8.5% 0.03 20.0% 16.7% 0.72 10.3% 6.3% 0.68 21.3% 4.2% 0.08 12.0% 9.5% 1.0 
Diabetes mellitus 26.1% 23.4% 0.81 31.4% 25.0% 0.55 28.2% 34.4% 0.58 34.0% 41.7% 0.53 38.0% 47.6% 0.45 
Coronary disease 47.8% 48.9% 0.93 48.6% 36.1% 0.29 38.5% 34.4% 0.72 38.3% 45.8% 0.54 58.0% 61.9% 0.76 
Hypertension 65.2% 66.0% 0.95 71.4% 69.4% 0.85 66.7% 65.6% 0.93 59.6% 75.0% 0.20 70.0% 71.4% 0.90 
Chronic heart failure 39.1% 55.3% 0.20 51.4% 44.4% 0.56 61.5% 50.0% 0.33 44.7% 58.3% 0.28 74.0% 66.7% 0.53 
Dementia 17.4% 25.5% 0.45 0.0% 2.8% 1.0 10.3% 0.0% 0.12 4.3% 4.2% 1.0 4.0% 4.8% 1.0 
Chronic liver disease 0.0% 2.1% 1.0 5.7% 0.0% 0.24 5.1% 3.1% 1.0 2.1% 16.7% 0.04 4.0% 0.0% 1.0 
Significant kidney 
dysfunction 
17.4% 14.9% 1.0 22.9% 16.7% 0.51 20.5% 28.1% 0.45 17.0% 29.2% 0.24 22.0% 9.5% 0.32 
Systemic cancer 26.1% 21.3% 0.65 20.0% 33.3% 0.20 25.6% 18.8% 0.49 12.8% 16.7% 0.72 26.0% 23.8% 0.85 
Anemia 47.8% 51.1% 0.80 40.0% 47.2% 0.54 33.3% 43.8% 0.37 42.6% 58.3% 0.21 66.0% 28.6% 0.004 
Medications                
Aspirin 21.7% 53.2% 0.01 11.4% 61.1% <0.001 10.3% 59.4% <0.001 14.9% 58.3% <0.001 10.0% 42.9% 0.003 
Other antiplatelet 
therapies 
0.0% 2.1% 1.0 0.0% 2.8% 1.0 0.0% 0.0% - 0.0% 0.0% - 0.0% 0.0% - 
Lipid lowering agents 0.0% 2.1% 1.0 0.0% 2.8% 1.0 0.0% 0.0% - 8.5% 8.3% 1.0 46.0% 28.6% 0.17 
ARBs 13.0% 4.3% 0.32 5.7% 5.6% 1.0 0.0% 6.3% 0.20 0.0% 4.2% 0.34 4.0% 0.0% 1.0 
Ace Inhibitors 4.4% 12.8% 0.41 25.7% 30.6% 0.65 53.9% 50.0% 0.75 57.5% 58.3% 0.94 62.0% 57.1% 0.70 
W+: using warfarin at time of GI hemorrhage; W-: not using warfarin at time of GI hemorrhage
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Appendix Table 3d: Baseline Patient Characteristics by Propensity Score Quintile among Patients with GI Hemorrhage from the 
ATRIA-CVRN Study for Longer-term Mortality (Highlighted variables were included in propensity score model) 
 Quintile1 Quintile2 Quintile3 Quintile4 Quintile5 
 W+ W- P W+ W- P W+ W- P W+ W- P W+ W- P 
Variable                
Age (years), mean (SD) 80.1 78.2 0.45 75.8 78.0 0.40 77.0 77.1 0.94 76.4 77.1 0.72 74.2 70.5 0.22 
Race, white 62.5% 63.6% 0.94 52.0% 66.7% 0.25 64.9% 58.3% 0.61 74.5% 71.4% 1.0 66.7% 60.0% 0.73 
Women 56.3% 59.1% 0.84 48.0% 50.0% 0.88 35.1% 37.5% 0.85 40.4% 28.6% 0.42 43.1% 40.0% 1.0 
Low educational attainment 37.5% 27.3% 0.53 32.0% 27.8% 0.72 29.7% 20.8% 0.44 25.5% 50.0% 0.11 21.6% 40.0% 0.24 
Low annual household 
income 
31.3% 15.9% 0.27 12.0% 11.1% 1.0 16.2% 8.3% 0.46 21.3% 14.3% 0.72 5.9% 20.0% 0.19 
Current Smoker, yes 25.0% 15.9% 0.46 12.0% 2.8% 0.30 8.1% 16.7% 0.42 14.9% 21.4% 0.68 3.9% 10.0% 0.42 
History of mechanical falls 25.0% 25.0% 1.0 20.0% 16.7% 0.75 13.5% 12.5% 1.0 10.6% 14.3% 0.66 7.8% 10.0% 1.0 
Prior GI hemorrhage 25.0% 27.3% 1.0 16.0% 22.2% 0.75 16.2% 16.7% 1.0 17.0% 14.3% 1.0 13.7% 0.0% 0.59 
Prior ischemic stroke 18.8% 9.1% 0.37 4.0% 11.1% 0.64 8.1% 8.3% 1.0 12.8% 14.3% 1.0 9.8% 10.0% 1.0 
Diabetes mellitus 43.8% 40.9% 0.84 48.0% 47.2% 0.95 59.5% 45.8% 0.30 29.8% 28.6% 1.0 37.3% 50.0% 0.50 
Coronary disease 31.3% 25.0% 0.74 36.0% 44.4% 0.51 43.2% 54.2% 0.40 46.8% 42.9% 0.79 45.1% 30.0% 0.49 
Hypertension 100% 97.7% 1.0 100% 94.4% 0.51 94.6% 95.8% 1.0 87.2% 100% 0.32 88.2% 80.0% 0.61 
Chronic heart failure 43.8% 45.5% 0.91 52.0% 52.8% 0.95 46.0% 45.8% 0.99 46.8% 42.9% 0.79 45.1% 50.0% 1.0 
Dementia 18.9% 25.0% 0.74 8.0% 5.6% 1.0 2.7% 4.2% 1.0 0.0% 0.0% - 0.0% 0.0% - 
Chronic liver disease 6.3% 6.8% 1.0 4.0% 0.0% 0.41 2.7% 16.7% 0.07 2.1% 0.0% 1.0 2.0% 0.0% 1.0 
Significant kidney 
dysfunction 
0.0% 4.6% 1.0 12.0% 22.2% 0.50 8.1% 12.5% 0.67 12.8% 7.1% 1.0 15.7% 0.0% 0.33 
Systemic cancer 18.8% 20.5% 1.0 8.0% 30.6% 0.03 32.4% 25.0% 0.53 17.0% 7.1% 0.67 33.3% 10.0% 0.26 
Anemia 56.3% 79.6% 0.10 76.0% 58.3% 0.153 59.5% 58.3% 0.93 48.9% 42.9% 0.69 51.0% 50.0% 1.0 
Lung disease 43.8% 45.5% 0.91 40.0% 47.2% 0.58 48.7% 37.5% 0.39 46.8% 42.9% 0.79 41.2% 50.0% 0.73 
Transient ischemic attack 6.3% 6.8% 1.0 12.0% 11.1% 1.0 10.8% 8.3% 1.0 2.1% 0.0% 1.0 5.9% 10.0% 0.52 
Medications                
Aspirin  75.0% 70.5% 1.0 60.0% 77.8% 0.13 51.4% 45.8% 0.67 42.6% 21.4% 0.21 17.7% 20.0% 1.0 
Other antiplatelet therapies 6.3% 15.9% 0.67 28.0% 11.1% 0.17 10.8% 12.5% 1.0 14.9% 21.4% 0.68 2.0% 10.0% 0.30 
Lipid lowering agents 43.8% 29.6% 0.30 60.0% 55.6% 0.73 56.7% 58.3% 0.90 61.7% 71.4% 0.51 72.6% 70.0% 1.0 
ARBs 6.3% 13.6% 0.66 8.0% 2.8% 0.56 24.3% 25.0% 0.95 10.6% 14.3% 0.65 5.9% 0.0% 1.0 
Ace Inhibitors 50.0% 31.8% 0.20 48.0% 47.2% 0.95 35.1% 37.5% 0.85 40.4% 57.1% 0.27 29.4% 30.0% 1.0 
W+: using warfarin at time of GI hemorrhage; W-: not using warfarin at time of GI hemorrhage 
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Appendix 4 – Association between warfarin intensity at the time of major GI hemorrhage and mortality in the ATRIA 
and ATRIA-CVRN cohorts 
 ATRIA ATRIA-CVRN 
 Warfarin use 
at GI 
hemorrhage*: 
INR ≥ 3 
Warfarin use 
at GI 
hemorrhage*: 
INR < 3 
No Warfarin 
at GI 
hemorrhage 
 
Warfarin use 
at GI 
hemorrhage*: 
INR ≥ 3 
Warfarin use 
at GI 
hemorrhage*: 
INR < 3 
No Warfarin 
at GI 
hemorrhage 
 
30-day Mortality n=112 n=89 n=191 n=111 n=82 n=151 
    Deaths, n (%)  15 (13.4%) 8 (9.0%) 25 (13.1%) 6 (5.4%) 1 (1.2%) 21 (14.0%) 
    Person-years 8.3 6.8 14.0 8.6 6.5 11.3 
    Rate Ratio 
(unadjusted) 
1.01 
(0.53–1.91) 
0.66 
(0.30–1.47) 
- 
0.37 
(0.15–0.93) 
0.08 
(0.01–0.62) 
- 
    Rate Ratio (adjusted)  1.16 
(0.59–2.27) 
0.75 
(0.33–1.70) 
- 
0.39  
(0.15–1.00) 
0.09 
(0.01–0.67) 
- 
       
Long-term mortality n=112 n=89 n=191 n=111 n=82 n=151 
    Deaths, n (%) 38 (33.9%) 22 (24.7%) 38 (19.9%) 15 (13.5%) 14 (17.1%) 36 (23.8%) 
    Person-years 76.0 69.4 127.7 73.4 56.2 83.9 
    Rate Ratio 
(unadjusted) 
0.80 
(0.54–1.17) 
0.53 
(0.33–0.85) 
- 
0.51 
(0.28–0.92) 
0.62  
(0.34–1.15) 
- 
    Rate Ratio (adjusted)  0.93 
(0.62–1.39) 
0.61  
(0.37–0.98) 
- 
0.54 
(0.29–1.01) 
0.71  
(0.37–1.35) 
- 
* ATRIA: n=22; ATRIA-CVRN: n=17 missing INR value at time of GI hemorrhage 
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Appendix 5 – Association between estimated duration of diabetes and incidence 
of ischemic stroke with three duration categories 
 
 
Non-
Diabetic 
Estimated 
Diabetes 
Duration < 3 
years 
Estimated 
Diabetes 
Duration 3–8 
years 
Estimated 
Diabetes 
Duration > 8 
years 
     
Ischemic stroke events 463 21 53 63 
Person-years (py) 25,801.8 1260.6 1830.4 2128.7 
Rate 1.8/100py 1.7/100py 2.9/100py 3.0/100py 
Hazard Ratio (unadjusted) n/a Reference 2.01 (1.21–3.34) 2.06 (1.25–3.40) 
Hazard Ratio (minimally 
adjusted*) 
n/a Reference 1.98 (1.19–3.28) 1.90 (1.15–3.15) 
Hazard Ratio (adjusted‡) n/a Reference 1.86 (1.12–3.09) 1.71 (1.03–2.84) 
Hazard Ratio (unadjusted) Reference 0.84 (0.55–1.30) 1.72 (1.29–2.28) 1.78 (1.37–2.32) 
Hazard Ratio (minimally 
adjusted*) 
Reference 0.97 (0.63–1.50) 1.96 (1.47–2.61) 1.89 (1.44–2.46) 
Hazard Ratio (adjusted‡) Reference 0.90 (0.58–1.40) 1.69 (1.26–2.26) 1.57 (1.20–2.06) 
* Adjusted for age, gender, race 
‡ Adjusted for age, gender, race, congestive heart failure, hypertension, prior ischemic 
stroke, coronary artery disease, and peripheral arterial disease
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Appendix 6 – Association between estimated duration of diabetes and incidence 
of ischemic stroke with diabetic patients restricted to those with prevalent 
diabetes 
 
 
Non-Diabetic 
Estimated 
Diabetes Duration 
< 3 years 
Estimated 
Diabetes Duration 
≥3 years 
    
 Ischemic stroke events 463 7 109 
 Person-years 25,801.8 332.2 3593.9 
 Rate 
1.8/100 
person-years 
2.1/100       
person-years 
3.0/100       
person-years 
 Hazard Ratio (unadjusted) - 0.93 (0.44–1.96) 1.77 (1.44–2.18) 
 Hazard Ratio (minimally adjusted*) - 1.08 (0.52–2.27) 1.94 (1.57–2.39) 
 Hazard Ratio (adjusted‡) - 0.97 (0.46–2.04) 1.63 (1.31–2.03) 
* Adjusted for age, gender, and race 
‡ Adjusted for age, gender, race, congestive heart failure, hypertension, prior ischemic 
stroke, coronary artery disease, and peripheral arterial disease
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Appendix 7 – Association between HbA1c and ischemic stroke among patients 
with prevalent diabetes 
 
 HbA1c < 7.0% HbA1c 7.0–8.9% HbA1c ≥ 9.0% 
 Ischemic stroke events 35 42 14 
 Person-years 1134.2 1257.4 510.3 
 Rate 3.1/100 person-
years 
3.3/100 person-
years 
2.7/100 person-
years 
 Hazard Ratio (unadjusted) - 1.09 (0.70–1.72) 0.87 (0.47–1.61) 
 Hazard Ratio (minimally adjusted*) - 1.16 (0.74–1.84) 0.99 (0.54–1.83) 
 Hazard Ratio (adjusted‡) - 1.16 (0.73–1.86) 0.96 (0.50–1.84) 
* Adjusted for age, gender, and race 
‡ Adjusted for age, gender, race, congestive heart failure, hypertension, prior ischemic 
stroke, coronary artery disease, peripheral arterial disease, proteinuria, significant kidney 
dysfunction, insulin use, and diabetes duration 
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